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General introduction and scope of the thesis 
 
 10 
Hematopoiesis throughout development 
 
The hematopoietic system has captivated the interest of many stem cell and regenerative medicine 
enthusiasts due to its unique property of constant renewal and regeneration of blood. The studies 
describing blood cell production in the vertebrate embryo were pioneered in the early 1900s [1, 2]. 
Hematopoiesis during early embryogenesis occurs in multiple waves and at several different anatomic 
sites [figure 1] [3]. The initial wave of the primitive hematopoiesis primarily leads to production of 
red blood cells (RBC) to facilitate the supply of oxygen and other essential factors needed for the 
rapidly growing embryo. This is followed by a wave of definitive hematopoiesis where the first 
hematopoietic cells and erythro-myeloid cells are generated at the extra-embryonic yolk sac and later 
in the allantois and placenta. They quickly change their location throughout development. The next 
anatomic site for hematopoiesis is the aorta-gonad-mesonephros (AGM) region where the next wave 
of definitive hematopoiesis takes place. It is at this site where adult hematopoietic stem cells (HSC) 
embark upon their important task of regenerating the entire hematopoietic system including lymphoid 
progenitors. Thereafter, they migrate to the placenta and fetal liver where they undergo expansion. 
Finally, they migrate to the spleen and around birth to the bone marrow (BM) where they remain 
throughout the adult life [3–6].  
 
Despite their rapid expansion during embryogenesis, adult HSCs are relatively quiescent and very 
difficult to maintain or even expand during in vitro culture conditions. Therefore, embryonic stem 
(ES) cells might be an alternative source of cells to expand HSCs for in vitro and in vivo experiments. 
Protocols have been optimized for the in vitro culture conditions of human as well as murine ES cells 
by e.g. the addition of cytokines [leukemia inhibitory factor (LIF), bone morphogenic protein 4 
(BMP4), basic fibroblast growth factor (b-FGF), WNT signaling agonists] or by co-culture with 
stromal cells [murine embryonic feeder cells (MEF), human foreskin feeder (HF)] or by regulating 
transcription factors [Sox2, Oct3, Oct4, Nanog] [7]. Along with the propagation of ES cells, efforts 
are being directed towards the physiological differentiation of embryonic stem cells into definitive 
adult hematopoietic cells, and although some successes have been reported, this remains challenging 
[7]. Recently, the establishment of an in vivo human hematopoietic system using induced pluripotent 
stem (iPS) cells was investigated for the first time through the formation of teratomas, within which 
cells can differentiate along all three germ layers, i.e. ectoderm, mesoderm, and endoderm. Despite 
various challenges and relatively low efficiencies, definitive engrafting hematopoietic stem and 
progenitor cells (HSPC) could be generated, probably due to the fact that within these teratomas bone 
like structures developed that probably provided essential BM physiological cues for proper 
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differentiation. This study highlights the role of a permissive niche as an essential part of the 











Figure 1: Timeline of embryonic hematopoietic development in mouse and man. This figure 
displays the anatomical sites and timing of the generation and trafficking of hematopoietic cells to 
other anatomical sites for their expansion and maintenance. dpc: days after conception; wpc: weeks 




Hematopoietic stem cells are at the root of the hematopoietic hierarchy from which different lineage-
restricted progenitors branch out. These HSCs possess unique properties of self-renewal, 
differentiation and thus reconstitute all blood cell lineages along with maintaining a pool of self-
renewing stem cells throughout the lifetime of an individual. According to the classical view, HSCs 
give rise to progeny that successively lose their ability to self-renew and restrict themselves to one 
particular lineage [9–11]. It describes the progressive loss of lineage potential from long-term HSCs 
(LT-HSC) to short-term HSCs (ST-HSC), to multipotent progenitors (MPP) and ultimately to either 
myeloid or lymphoid lineage precursors by generating common myeloid and lymphoid progenitors 
(CMP or CLP) respectively [figure 2A].  However, some conflicting studies have raised legitimate 
questions regarding this scheme of lineage commitment. Recently, an alternative  model proposed by 
Sten Eirik Jacobsen and colleagues describes the successive differentiation of ST-HSCs/MPPs into 
lymphoid-primed multipotent progenitors (LMPP) which lack erythroid and megakaryocytic  
potential and megakaryocyte/erythroid progenitors (MkEP) that cannot form other myeloid/lymphoid 
lineages [figure 2B][12]. In summary, through stepwise differentiation or non-linear branching a 
single multipotent dormant HSC can give rise to new HSCs via self-renewal, B cells, T cells, 
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megakaryocytes, erythrocytes, granulocytes, monocytes, natural killer, platelets and dendritic cells 















Figure 2: Proposed models for hematopoietic stem cell lineage commitment. A] Classical model 
that postulates a gradual loss of MPP lineage potential further resulting exclusively into bifurcation 
of common myeloid and lymphoid progenitors. B] Current model based on recent studies, showing 
the presence of LMPPs which lack significant Mk and E potential but sustain other blood lineage 
developmental potential. LT-HSC: long-term hematopoietic stem cells; ST-HSC: short-term 
hematopoietic stem cells; MPP: multipotent progenitor; LMPP: lymphoid-primed multipotent 
progenitor; MkEP: megakaryocyte/erythroid progenitor; CMP: common myeloid progenitor; CLP: 
common lymphoid progenitor; GMP: granulocyte/macrophage progenitor; B: B cell; T: T cell. 
Adapted from: [12]  
 
Malignant hematopoiesis  
 
The notion that tumors arise from stem cells was first proposed by Julius Cohnheim in 1875 [14, 15]. 
However, the existence of cancer stem cells was for the first time formally and experimentally shown 
in the case of acute myeloid leukemia (AML) where leukemic stem cells (LSCs) could be identified 
[16–19]. The studies from the group of John Dick [16–19] for the first time ever showed that AML 
is organized as a hierarchy, not dissimilar to the normal hematopoietic hierarchy. They were able to 
enrich for rare LSCs by sorting CD34+CD38- AML cells that were able to engraft in SCID/NOD-
SCID xenograft mice and possessed key stem cell properties. Later on, several studies challenged the 
A Classical model            B Current model 
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notion that LSCs were restricted to this particular subset of cells and addressed the heterogeneity in 
leukemia. The group of Dominique Bonnet identified leukemia-initiating cells (LICs) within the 
CD34+CD38+ compartment as well as in CD34- fractions in the majority of primary NPM1-mutated 
AML [20, 21]. In a separate study, Sarry and colleagues assayed the heterogeneity of LSCs using 
NSG mice and found that indeed LICs can also reside in more mature fractions; i.e. the GMP-like 
subset (CD34+CD38+CD45RA+), the CMP-like subset (CD34+CD38+CD45RA+CD123+), and the 
CD34- subsets [22], highlighting the fact that LSCs may not necessarily reside within one particular 
subset.  
 
In acute lymphoid leukemia (ALL) there exist discrepancies in LSC characterization. One study 
suggested that for pre-B cell ALL, LSCs are primitive and lack CD19 expression [23] while another 
study supported the notion that LSCs are committed and do express CD19 [24]. In pediatric T-ALL, 
both CD34+/CD4- and CD34+/CD7- primitive cells were the target for leukemic transformation [25].  
 
While various cell compartments can act as either cell of origin or cell of maintenance that drive 
leukemia progression, it is most compelling to suppose that like HSCs, LSCs are also hierarchically 
organized. A striking resemblance between HSCs and LSCs in terms of cell-surface markers, 
quiescence and self-renewal pathways (for example Wnt/β-Catenin [26], BMI1 [27]) signify that 
LSCs might have derived from HSCs in the line of reasoning that activating a de novo self-renewal 
program would be less efficient for an LSC than simply modulating the already existing one. On the 
other hand, some studies have reported that distinct non-stem cells could be converted to LSCs if the 
correct self-renewal program is installed in these cells. For instance, studies by Sengupta and 
colleagues reported that BMI1 reprograms CML B-lymphoid progenitors to initiate B-ALL, 
supporting the idea that committed progenitor can indeed acquire LSC potential [28]. Another 
example is MLL-AF9, which can impose self-renewal characteristics and leukemic transformation 
potential on committed GMPs [29].  
 
Leukemias are by enlarge caused by mutations in our DNA and genetic factors intrinsic to LSCs that 
govern the maintenance and progression of disease are equally important. Whole genome and exome 
sequencing efforts such as those from The Cancer Genome Atlas (TCGA) consortium [30] have 
uncovered the mutational landscape of acute myeloid leukemia. Over 200 different mutations have 
now been identified, including chromosomal translocations, deletions, amplifications and mutations 
in transcription factors, kinases, signaling molecules, cohesins, spliceosome factors and epigenetic 
regulators [30]. In most cases, multiple mutations together are necessary for the development of a full 
blown leukemia, and as initially proposed by Gilliland these might be classified as class I mutations 
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causing a proliferative or survival advantage and class II mutations that would impair differentiation 
[31]. Indeed as illustrated in some cases, the initiating events, that occur at the level of HSCs (AML1-
ETO in AML and BCR-ABL in CML) are necessary but not sufficient in model systems, and diverse 
additional mutagenic events are necessary to drive leukemia to an aggressive phase [32]. A thorough 
understanding of how genetic alterations impact on stem cell self-renewal, differentiation and 
survival is essential to begin to understand the process of leukemic transformation. For example, 
using next generation sequencing approaches the recurrent molecular mutations in IDH1 and 
DNMT3A were identified, along with other frequent mutations like FLT3-ITD and NPM1 in AML 
[33, 34] thus allowing the determination of insertion site, ITD length, allelic ratio, clonal dominance 
as well as relative abundance of each clone over time [35]. Furthermore, karyotypic abnormalities in 
myeloid malignancies included deletion or mutation of a tumor-suppressor gene, TET2 [36] along 
with homozygous mutations in EZH2 [37]. Like AML, frequent genetic abnormalities were also 
observed in B-ALL including t(9;22) BCR-ABL, t(12;21) TEL-AML1, and various other MLL fusion 
proteins [38, 39]. Recently, multicolor fluorescence in situ hybridization (FISH), as well as single-
nucleotide polymorphism array in conjugation with xenotransplantation assay, was used to 
discriminate subclones in pediatric ALL samples [40, 41]. Genetic heterogeneity was observed in 
ALL-initiating/propagating cells from a single patient. Additionally, these data indicated that multiple 
tumor clones coexist in the diagnostic patient sample and that these clones undergo divergent 
evolution from the diagnostic clone, supporting the branching model of tumor progression [42]. 
Furthermore, molecular heterogeneity of leukemia also depends on methylation profiles controlled 
by epigenetic regulators. Aberrant hypermethylation and silencing of tumor suppressor genes have 
been widely reported in leukemias [43–45]. DNA methylation profiling which was used for clinical 
stratification of AML indicated that epigenetic diversity contributes to heterogeneity in leukemia 
[46]. Thus, the heterogeneity of LSCs further complicates the development of effective targeting 
strategies to eliminate LSCs to prevent relapse of disease. 
 
Chronic myeloid leukemia (CML) 
 
Chronic myeloid leukemia (CML) is a stem cell disease characterized by the presence of the 
Philadelphia (Ph) chromosome due to a reciprocal translocation between chromosome 22 and 
chromosome 9 t(9;22) [47–49]. This leads to the formation of BCR-ABL fusion protein depending 
on precise breakpoint and splicing of final BCR-ABL mRNA thus generating p210, p190 and p230 
fusion proteins [47, 50]. The resulting chimeric BCR-ABL gene encodes for a constitutively active 
oncoprotein, the BCR-ABL tyrosine kinase which contains series of functionally distinct domains 
[50]. The ABL protein, when fused with BCR, loses its property to shuttle between nucleus and 
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cytoplasm and thus remains in the cytoplasm where it interacts with various proteins [51–55]. This 
leads to downstream activation of several pathways like STAT5, MAPK, PI3K, β-Catenin and much 
more, leading to a disturbance of normal cellular functions. As a consequence, transcriptional 
networks are deregulated resulting in prolonged survival, expansion of leukemic cells and hence 
progression to CML disease [56]. 
 
It is clear that the BCR-ABL translocation in the most primitive hematopoietic stem cells is necessary 
and sufficient to initiate the Chronic Phase (CP) of disease [57, 58]. However, it needs collaborating 
events for maintenance and progression of CML to Accelerated Phase (AP) and further to the Blast 
Crisis phase (BC) [figure 3]. One such collaborating factor is the polycomb group member BMI1. 
BMI1 is a negative regulator of the p16INK4/p19ARF locus and plays a critical role in maintaining 
self-renewal of normal and leukemic HSCs [28, 59–63]. Other pathways, such as the WNT and 
Hedgehog pathways, have also been implicated to play a role in the maintenance of BC CML stem 
cells [64–67]. Furthermore, activation of beta-Catenin in granulocyte-macrophage progenitors 
(GMP) has been shown to re-install self-renewal properties. While the disease originates from HSCs 
in which the t(9;22) translocation first occurs, it appears that upon progression of the disease 
leukemic-GMPs also participate in maintenance of CML [65]. A further understanding of the 
mechanisms involved in progression and maintenance of CML LSCs may lead to the development of 




Figure 3: Initiation and progression of CML to blast crisis. The t(9;22) translocation resulting in 
BCR-ABL expression in the most primitive HSC gives rise to initiation of the chronic phase (CP) of 
disease. CP-CML generally lasts for few months/years and then further progresses to the accelerated 
phase (AP) or directly to the blast crisis (BC) phase of the disease, ultimately developing either 
lymphoid or myeloid leukemia. Various downstream signaling pathways are activated and many 




CML is regarded as a classical example of cancer defined by the unique Ph+ chromosome. The 
insights into the genetic alterations coupled to insights into functional changes greatly facilitated the 
structural and functional studies to design targeted therapies in cancer medicine for the first time ever. 
From busulfan, hydroxyurea, interferon-alpha (IFN) to the landmark discovery of imatinib mesylate 
(IM), a tyrosine kinase inhibitor: CML therapeutics are therefore at the forefront in the human race 
against cancers [68]. Current CML therapy is primarily based on imatinib, which functions as a 
competitive inhibitor for binding to the ATP pocket in the kinase domain and acts as a potent tyrosine 
kinase inhibitor (TKI). Treatment of CML patients with this inhibitor leads to response rates of over 
95% [69, 70]. Yet, the leukemia-initiating cells are not targeted efficiently [47;54;55], and patients 
might need to stay on therapy life-long. Furthermore, imatinib rendered to be ineffective due to 
acquired frequent mutations in the kinase domain of BCR-ABL.  The point mutations in the activation 
loop, phosphate binding P-loop or in the ATP-binding region are responsible for primary imatinib 
resistance [71]. Shortly after the realization that imatinib-insensitivity was caused by these mutations, 
second and third generation tyrosine kinase inhibitors were developed. Although dasatinib and 
nilotinib were potent against imatinib-resistant CML, still patients with T315I mutation suffered. 
Ponatinib, a third generation TKI is the first TKI that has been reported to work efficiently in patients 
with T315I mutations [72].  
 
Significant advances have been made in CML treatment, from identifying the genetic cause(s) to the 
development of TKIs to control CML with oral medications. Latest STOP clinical trial studies 
presented at ASH 2014 suggests that stopping treatment in stable long-term deep molecular remission 
seems feasible however regular molecular monitoring and quick re-initiation of therapy in case of 
loss of major molecular response may be essential. It has been recommended not to stop treatment 
outside of clinical trials for now [73, 74].   
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Furthermore, what is to some extent being overlooked is TKI-independent resistance. Apart from 
kinase domain mutations; through E-selectin-ligand interactions [75], overexpression of the 
chemokine receptor CXCR4 [76], adaptation to hypoxia [77, 78], restricted imatinib uptake due to 
variability in expression and activity of influx and efflux transporters [79] and via activation of BCR-
ABL-independent survival mechanisms [80], CML cells tend to acquire protection through extrinsic 
as well as intrinsic cues. Selection of resistant clones, possibly due to a ‘‘protective 
microenvironment’’, increased efflux of drugs or BCR-ABL-independent signaling mechanisms 
leave refractory CML manageable but incurable beyond the realm of allogeneic stem cell 
transplantation and lifelong TKI treatment.  
 
Modeling of CML using xenograft models 
 
Establishment of diverse murine models has largely contributed to understanding CML 
leukemogenesis. These models range from (conditional) transgenic models [28, 81], knock-in models 
[82], and murine bone marrow retroviral transduction models followed by transplantation [83]. With 
the advancement of immunodeficient xenograft models, it has become possible to use human 
stem/progenitor cells for in vivo studies as well as cells directly derived from CML patients. These 
models not only mimic CML but have also been instrumental in uncovering various fundamental 
mechanisms of CML disease progression and tyrosine kinase inhibitor (TKI) resistance. However, 
these current models are still far from optimal. Although, the murine and human bone marrow niches 
show clear similarities, differences also exist. Most important might be that certain myeloid growth 
factors and cytokines (e.g. IL3, TPO, and SCF) are species-specific [84–87], and murine factors 
arising from the mouse bone marrow niche will therefore not act on human cells. These cytokines are 
known to play important instructive roles in regulating stem cell fate, and are probably also critically 
important for LSCs [5]. Furthermore, properties of human LSCs might differ compared to mouse 
HSCs in terms dependency of niche factors with regard to their engraftment potential [88–91]. Thus, 
apart from using immune-compromised mouse models that can host human grafts, providing an 
optimal niche for the engraftment and maintenance of CML LSCs is essential in order to unravel their 
molecular characteristics.  
 
The microenvironment and CML  
 
The bone marrow microenvironment consists of a wide variety of cell types, including osteoblasts, 
osteoclasts, mesenchymal stem cells, sinusoidal endothelium, perivascular stromal cells, immune 
cells like macrophages, and regulatory T cells. Normal HSCs reside in a stem cell-specific 
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microenvironment in the bone marrow where they are nurtured, regulated and undergo self-renewal 
[92]. Recent studies also highlight a critical role for the bone marrow niche in protecting and 
maintaining LSCs [89–91, 93–97]. The N-Cadherin and Wnt/beta-Catenin signaling pathways have 
been associated with protecting CML stem/progenitor cells from TKI treatment [89]. Other 
alterations in the microenvironment associated with CML include an increased expression of 
chemokines, cytokines such as IL-1alpha, IL-1beta, IL-6, G-CSF, TNFalpha, LIF as well as 
alterations in the BMP pathway during early stages of CML development, which confer a selective 
advantage  to LSCs [91, 97]. Interestingly, remodeling of the endosteal BM niche was observed due 
to development of BCR-ABL-positive myeloproliferative neoplasia, whereby MSCs were stimulated 
to produce functionally altered osteoblasts [90]. Furthermore, studies from Ng and colleagues 
indicated that the bone marrow hypoxic environment supports the persistence of CML LSCs, even in 
presence of imatinib [98]. In conclusion, multiple mechanisms are involved in altering the balance 
between LSCs versus healthy stem/progenitor cells in the bone marrow niche, including alterations 
in direct niche interactions, alterations in chemokine/cytokine production thereby inducing an 
inflammatory environment,  or alterations in cellular niche components [figure 5]. A thorough 
understanding of these niche alterations might open up new avenues for selective strategies to 
eradicate CML LSCs.  
 
Altered metabolism in CML 
 
Increased glucose uptake and thereby enhanced glycolysis under aerobic conditions (also known as 
the Warburg effect) has been associated with various cancers, including BCR-ABL-induced 
leukemogenesis [99, 100]. These BCR-ABL positive cells undergo rapid proliferation and hence an 
increased glycolysis rate for bioenergetic needs but also to prevent the detrimental effects of too high 
mitochondrial activity and ROS production seems logical. Moreover, imatinib-resistant cells have 
been shown to depend even further on glycolysis by maintaining high SLC2A1 expression on the 
plasma membrane of BCR-ABL-positive cells [101].  
 
Past studies from the group of Thompson and colleagues have shown the dependency of BCR-ABL 
imatinib-resistant cells on the Warburg effect mediating decreased cell proliferation via induction of 
HIF1-alpha even under normoxic conditions [102]. Hypoxia inducible factors (HIF1a and HIF2a) are 
transcription factors which are stabilized under hypoxia in normal stem/progenitor cells. However, 
an increasing number of studies has suggested non-hypoxic stabilization of HIFs either through 
cytokines or through the PI3K pathway [103–105]. As suggested by studies from the group of Dang 
and colleagues HIF1a inhibits pyruvate dehydrogenase (PDH) and activate pyruvate dehydrogenase 
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kinase (PDK2/4) thereby shunting pyruvate from mitochondria and feeding it into lactate production. 
Thus, these data suggest that the HIF1a-mediated metabolic switch is important to prevent HSCs 
from toxic ROS production at the cost of lower ATP production via glycolysis [106]. Earlier studies 
from various groups have shown that BCR-ABL-induced HIF1a redirects glucose metabolism away 
from mitochondria suggesting a decreased synthesis of amino acids, fatty acids and other 
biomolecular substrates [105, 107]. Thus, such needs of actively proliferating leukemic cells are not 
met by a sole dependency on glycolysis. Moreover, while considering therapeutic strategies, it is of 
utmost importance to take into account compensatory contributions of other cellular metabolite 
sources. Recent studies from the group of Le and colleagues suggest glucose-independent 
mitochondrial oxidative phosphorylation under hypoxic conditions in the presence of glutamine in 
P493 cells, a human B- cell Burkitt lymphoma cell line. Thus, glutamine can serve as an alternative 
source of carbon since TCA intermediates generated by glucose metabolism can also be generated by 
glutaminolysis [108]. Furthermore, glutamine being an obligate source of nitrogen is needed for the 
biosynthesis of amino acids, nucleotides, etc. The other fate of glutamine can also be reductive 
carboxylation, thereby producing citrate for entry into fatty acid synthesis. Glutamine, being the most 
abundant amino acid in human plasma, has been shown to be essential for enhancing mitochondrial 
metabolism in c-MYC-transformed or IDH mutant AML [109][figure 4]. Thus, a further 
understanding of the regulation of metabolic switches to fulfill the survival needs under hypoxic or 
normoxic conditions of cancer cells should aid in the development of novel therapies aimed at 




Figure 4: Overview of metabolic pathways in normal and leukemic cells. Enhanced Warburg 
effect (i.e. maintenance of active glycolysis even in absence of oxygen) is key feature of many cancer 
























































































































or can take part in reductive carboxylation for fatty acid synthesis. Metabolites, enzymes or pathways 
in red coloured font indicates enhanced uptake, de-regulation in leukemic cells.   
 
Scope of the thesis  
 
As discussed before, various features impact on the progression of CML, including genetic diversity, 
clonal heterogeneity, epigenetic alterations and the presence of a permissive bone marrow niche. 
Stem cell self-renewal, survival and differentiation are regulated by an intricate interplay between 
intrinsic and extrinsic factors [figure 5]. Although these intrinsic and extrinsic factors are not always 
necessarily separate entities and crosstalk between these entities does exist. Intrinsic factors include 
for instance epigenetic regulators and alterations in metabolic pathways induced by the expression of 
oncogenes, while extrinsic factors include cues that HSCs receive from their supportive bone marrow 
niche. Thus, intrinsic as well as extrinsic signals, either alone or in coordination, control stem cell 
fate and survival of both normal as well as leukemic stem cells (LSC). The same is most likely true 
for LSCs. Genetic alterations as well as changes in the epigenetic landscape endow BCR-ABL cells 
with additional self-renewal properties and metabolic rewiring in a cell-intrinsic manner. The 
influence of the bone marrow niche as extrinsic factor provides the appropriate microenvironment for 
LSCs, including the presence of ligands, chemokines, cytokines, nutrients and a hypoxic milieu, 
which might all also impact on self-renewal, survival and their metabolic state. Thus, extrinsic and 
intrinsic cues together contribute to the fate of LSCs in BCR-ABL-mediated CML malignancy. With 
these features in mind, we set out to develop models that would faithfully recapitulate CML in order 





Figure 5: Extrinsic and intrinsic cues regulating BCR-ABL leukemogenesis. The bone marrow 
microenvironment consists of a complex interplay between extrinsic and intrinsic regulators. 
Cytokines, chemokines, various secreted factors, adhesion factors as well as the availability of certain 
nutrients like glucose, glutamine and hypoxia provides a protective milieu for LSCs in general [110]. 
These extrinsic factors directly or indirectly induce BCR-ABL LSCs survival signaling cascades, 
activate pro-survival pathways, alter metabolic signaling, resulting in survival and maintenance of 
BCR-ABL LSCs. Furthermore, intrinsic signaling involving the developmental pathways like BMI1, 
Hedgehog , WNT/b-catenin signaling have been known for expansion of blast crisis (BC)-CML LSCs 
and may be in part mediated through the niche. Thus the cross-talk between cell-autonomous and 


























An intriguing notion is the observation that the BCR-ABL oncogene can transform human CD34+ 
cells along the myeloid or the lymphoid lineage, giving rise to BC-CML or B-ALL, although 
underlying mechanisms that dictate this lineage fate are poorly understood. Cell-extrinsic cues might 
influence the outcome of the phenotype of CML by providing a specialized microenvironment for 
supporting either BC-CML/AML or ALL, provided that these LSCs indeed differ in their needs. 
Understanding the dependency of CML LSCs for such specialized microenvironments by the 
establishment of humanized niche xenograft models was a prime focus of this thesis. Furthermore, 
such extrinsic cues may not completely be able to override the cell-intrinsic program, and intrinsic 
mechanisms independent of environmental factors may of course also impact on altered signaling 
pathways that for instance change the metabolic status of cells. Here we set out to study how different 
oncogenes would impact metabolism of leukemic cells and in particularly focused on dependency for 
hypoxia-like signaling mechanisms in BCR-ABL stem/progenitor cells.   
 
Currently, the NSG [NOD/Lt-SCID/IL2Rγnull] xenotransplantation mouse model is the model of 
choice to evaluate human hematopoietic engraftment and to study the development of human 
leukemia. However, it has been a long way from mouse transduction/transplantation studies to the 
development of immunocompromised SCID mice and NSG mice to mimic the patient phenotypes for 
understanding CML leukemogenesis. A concise review of all murine and human xenograft models 
established till date and advantages and limitations of upcoming approaches are being discussed in 
chapter 2 of this thesis.  
 
Human engraftment in NSG mice is typically lymphoid biased. Since many growth factors and 
cytokines are species-specific we hypothesized that the presence of human niche would suffice the 
purpose of mimicking CML in vivo. Chapter 3 describes the establishment of a humanized niche 
xenograft model evaluating CML engraftment and leukemic transformation potential in vivo. We 
observed that, in contrast to the murine bone-marrow niche (mBM), BCR-ABL overexpression was 
sufficient to induce both AML and ALL, that could be serially transplanted. Efficient engraftment of 
blast-crisis CML patient cells was also observed whereby the immature blast-like phenotype was 
maintained in the human bone-marrow scaffold niche while more differentiated cells were observed 
in the mBM niches. In conclusion, we have established human niche models in which the myeloid 
and lymphoid features of BCR-ABL+ leukemia can be studied in detail. 
 
Enhanced glycolysis in aerobic conditions (also known as the Warburg effect) in cancer cells has 
been widely described, but molecular mechanisms underlying these phenomena remain poorly 
understood. We combined transcriptome and metabolome profiling in order to understand how 
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different oncogenes would impact on the metabolism of leukemic cells. Chapter 4 highlights the 
glutamine dependency in BCR-ABL+ stem/progenitor cells along with pronounced glycolysis. The 
transcriptomes of human CB CD34+ cells transduced with various oncogenes, including BCR-ABL, 
MLL-AF9, FLT3-ITD, NUP98-HOXA9, STAT5A and KRASG12V were analyzed in detail. Our 
data indicate that in particular BCR-ABL, KRASG12V and STAT5 could impose hypoxic signaling 
under normoxic conditions. This coincided with an upregulation of glucose importers SLC2A1/3, 
hexokinases and HIF1 and 2. NMR-based metabolic profiling was performed in CB CD34+ cells 
transduced with BCR-ABL versus controls, both cultured under normoxia and hypoxia. Lactate and 
pyruvate levels were increased in BCR-ABL-expressing cells even under normoxia, coinciding with 
enhanced glutaminolysis which occurred in an HIF1/2-dependent manner. Expression of the 
glutamine importer SLC1A5 was increased in BCR-ABL+cells, coinciding with an increased 
susceptibility to the glutaminase inhibitor BPTES. 
 
We conclude with chapter 5 summarizing the obtained results and discussing the current challenges 
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Over the past years, a wide variety of in vivo mouse models has been generated in order to unravel 
the molecular pathology of Chronic Myeloid Leukemia (CML) and to develop and improve 
therapeutic approaches. These models range from (conditional) transgenic models, knock-in models, 
and murine bone marrow retroviral transduction models followed by transplantation. With the 
advancement of immunodeficient xenograft models, it has become possible to use human 
stem/progenitor cells for in vivo studies as well as cells directly derived from CML patients. These 
models not only mimic CML but have also been instrumental in uncovering various fundamental 
mechanisms of CML disease progression and tyrosine kinase inhibitor (TKI) resistance. With the 
availability of induced pluripotent stem cells (iPSC) technology, it has become feasible to derive, 
maintain and expand CML subclones that are at least genetically identical to those in patients. The 
following review provides an overview of all murine as well as human xenograft models for CML 



































CML is a myeloproliferative disorder characterized by an accumulation of several types of myeloid 
precursor cells. CML is caused by a reciprocal translocation between chromosomes 9 and 22, also 
known as the Philadelphia (Ph+) chromosome, which leads to the formation of BCR-ABL fusion 
protein depending on precise breakpoint and splicing of final BCR-ABL mRNA [1].  More than 90% 
of the patients are diagnosed at a relatively early stage of the disease known as chronic phase (CP). 
It is generally accepted that acquisition of the t(9;22) BCR-ABL translocation is the initiating event 
in the CP-CML [2,3]. It is believed that this acquisition initially occurs in a single HSC that gains a 
proliferative advantage and/or aberrant differentiation capacity over the normal cells, giving rise to 
an expansion of the myeloid compartment [4,5]. Before the discovery of the tyrosine kinase inhibitors 
(TKIs), all patients with CP-CML progressed to advanced disease in a median of 5 years after 
treatment. This phase is divided into an accelerated phase (AP) followed by a myeloid blast crisis 
(BC) [6] although the transition to a lymphoid blast crisis can occur as well. The molecular 
mechanisms underlying this disease progression are still not entirely understood, but it is likely that 
they involve activation of oncogenic factors and inactivation of tumor suppressors. The phenotype of 
the self-renewing leukemic stem cells that maintain CML remains obscure. In CP-CML, LSCs reside 
within Lin-CD34+38- fraction, suggesting that the first cell that gains the BCR-ABL translocation is 
a stem cell or immature progenitor cell [7-9]. By performing engraftment studies in SCID (severe 
combined immunodeficiency) mice, Cobaleda C. et al. showed that the self-renewal, as well as 
phenotypic properties of leukemia-initiating cells (SL-ICs) in BCR-ABL p190 Ph-ALL, were similar 
to that of normal stem cells, suggesting that HSCs act as a cell of origin in CML [10]. Many other 
studies have also supported this idea and established a basic understanding of the CML hierarchy 
[11,12]. Furthermore, in contrast to other oncogenes like MOZ-TIF2 and MLL-ENL, BCR-ABL 
cannot confer self-renewal properties on committed progenitor cells, again suggesting that an 
immature stem/progenitor cell is most likely the cell of origin in CML [13-15]. Upon progression to 
BC-AML, it has been shown that the phenotype of the leukemia-maintaining stem cell changes and 
starts to resemble the phenotype of granulocyte/macrophage progenitors (GMPs). Jamieson et al 
reported in vitro self-renewal capacity of leukemic GMPs due to increased levels of nuclear β-Catenin 
compared to normal GMPs [16]. Furthermore, Minami Y et al provided evidence that BCR-ABL 
transformed GMPs with abnormal β-Catenin activity can function as LSCs that maintain the disease 
[17]. These data demonstrate that LSCs that initiate and later on maintain CML can possess versatile 
characteristics that change upon a progression of the disease.   
 
 36 
Treatment of CML patients with the inhibitor Imatinib leads to response rates of over 95% [18]. Yet, 
the leukemia-initiating cells are not targeted efficiently [12,19,20], and patients might need to stay on 
therapy life-long. A significant proportion of patients develops primary resistance to therapy, often 
due to mutations in the activation loop, phosphate binding P-loop or in the catalytic kinase domain 
of BCR-ABL [21-23]. Second and third generation TKIs have been developed such as Dasatinib, 
Nilotinib, Ponatinib, and Befatinib but TKI resistance appears to remain a challenge. Furthermore, 
acquired resistance during the course of therapy whether due to resistant clonal selection by protective 
microenvironment, increased efflux of drug or BCR-ABL signaling mechanism renders TKI 
ineffective for CML treatment [24-26].  Thus, identification of additional targets that facilitate the 
eradication of BCR-ABL+ leukemia-initiating cells is needed. 
 
Having assessed the cause of disease, the goal lies in identifying characteristics of remnant CML 
LSCs which lead to disease progression, TKI resistance, and relapse of disease. One approach centers 
on modeling CML in appropriate in vivo mouse models in order to study the molecular pathogenesis 
of this disease and develop and improve therapeutical approaches. This review summarizes the recent 
advances, current challenges and ongoing research in establishing mouse as well as a human 
xenograft in vivo model. Advantages and limitations of upcoming approaches such as iPSC 
technology and humanized xenograft mouse models for CML will be discussed as well (Figure 1) 





Figure 1: CML human and murine models till date. This figure summarizes established models 
for CML using chimeric mouse strains as well as different immunocompromised strains. Different 
experimental approaches and strategies along the time are also highlighted. ‘*’ refers to generation 
of serially transplantable leukemia and reference numbers (as indicated in table1) are denoted for 
each mouse model. 
 
Transgenic mice models 
 
- Conventional models  
The first transgenic model to assess the oncogenic potential of BCR-ABL was developed by 
introducing a synthetic BCR-ABL gene into the mouse germ line. A fusion of bcr and v-abl was 
expressed under the control of the immunoglobulin heavy-chain enhancer (Eµ) or to the 
promoter/enhancer of the long terminal repeat (LTR) of the myeloproliferative sarcoma virus 
(MPSV) [27]. The enhancers of both constructs were capable of functioning in diverse hematopoietic 
cells including B/T lymphocytes as well as some myeloid cell lines, reasoning that they might be also 
functional in primitive HSCs from which these progenitors arise. The expression of the transgene 
during early development resulted in decreased offspring yield. Furthermore, only 3 out of 12 mice 
bearing Eµ-driven BCR-ABL expression succumbed to pre-B and T lymphomas while 1 out of 3 
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mice harboring MPSV LTR-driven BCR-ABL expression developed T lymphomas. No myeloid 
leukemias were developed with either construct. Another disadvantage was that BCR-v-ABL differed 
from BCR-ABL in that it lacked parts of the bcr- and abl-derived regions and it had several amino 
acid substitutions in the latter. Thus, the results obtained with the p210 BCR-v-ABL transgenic mice 
may not accurately reflect the biological properties of the original hybrid protein [27].  
 
A more consistent outcome was achieved by using the delta metallothionein-1 promoter. This 
promoter is constitutively active in all tissues and was used to drive expression of the p190 BCR-
ABL gene. Ten out of 60 p190/deltaMT transgenic mice were obtained out of which 8 succumbed to 
death due to myeloid (2/8 mice) and lymphoid (6/8 mice) leukemia between 10-58 days of birth [28]. 
In follow-up studies with a bigger cohort of mice transplantable ALL/Lymphoma was shown with 
same construct [28,29]. Furthermore, in animals expressing the p210 BCR-ABL construct under 
control of the MT promoter T cell leukemias developed with no signs of B-ALL as was seen in p190 
BCR-ABL mice [30].  
 
In another study, the same group used the tec promoter to drive p210 BCR-ABL expression in 
transgenic mice. The tec gene encodes for a cytoplasmic kinase that is preferentially expressed in 
hematopoietic precursor cells. Using this transgenic model, 5 founders were generated out of which 
2 developed ALL shortly after birth while transgenic progeny exhibited MPDs resembling human 
CML after a much longer latency of 4-8 months [31]. These results indicated that tec-driven p210 
BCR-ABL transgenic mice could exhibit fundamental features of CML malignancy. 
 
- Conditional models  
 
Huettner C. and colleagues took a new approach by establishing a conditional transgenic mouse 
model for CML [32]. Transgenic mice with p210 BCR-ABL under the control of a tetracycline 
response element (TRE) were generated and offspring of 4 such trans responder transgenic mice were 
mated with transactivator mice (tTA under the control of MMTV-LTR) under the continuous 
administration of tetracycline in the drinking water, starting 5 days prior to mating. Double transgenic 
mice were obtained with the estimated Mendelian frequency in all 4 lines. Upon tetracycline 
withdrawal, BCR-ABL (also known as BCR-ABL1) was expressed and 100% incidence of lethal B-
ALL was observed without any signs of myeloid or T cell malignancy. This was probably due to B 
cell type specific promoter, the MMTV-LTR directing expression of tTA to B220+ cells. However, 
this study was the first of its kind to show blast cell counts in advanced-stage leukemic mice were 
reduced upon tetracycline administration to block BCR-ABL expression. These data indicated that 
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BCR-ABL1 was important for both the induction as well as the maintenance of the disease in these 
mice. Nevertheless, all reverted mice from one of the founder lines did succumb to BCR-ABL-
independent B-ALL in 2-4 weeks probably due to an acquisition of secondary mutation(s) during 
disease progression [32]. 
 
Later studies from the same group further modified this tet-off inducible transgenic model by placing 
tTA expression under control of the 3’enhancer of the murine stem cell leukemia (scl) gene [33]. SCL 
is a critical regulator of hematopoiesis and is normally expressed in erythroid and megakaryocytic 
cells, mast cells, as well as multipotent stem/progenitor cells. In these mice, induction of BCR-ABL 
resulted in neutrophilia and leukocytosis, bone marrow hyperplasia and extramedullary myeloid 
infiltration, thereby recapitulating many features of CML [33]. Furthermore, 31% of animals with 
myeloproliferative disease progressed to B-ALL [33]. Also, a reversion of the myeloid and lymphoid 
phenotypes was shown upon loss of BCR-ABL expression, although further experiments were 
required to assess whether loss of BCR-ABL can be tolerated during advanced stages of the disease.  
 
- Homologous recombination approach  
 
Homologous recombination was used as an alternative approach to create p190 BCR-ABL transgenic 
mice by inserting the BCR-ABL cDNA into exon1 of the mouse bcr locus. The construct was 
electroporated into ES E14 cells thereby generating ES cells that contained 1 intact bcr allele and 
another rearranged allele due to the BCR-ABL fusion. When these correctly modified ES cells were 
injected into recipient C57BL/6 blastocytes all chimeric mice developed B-ALL. Similar leukemia 
phenotypes were observed in 37 out of 40 chimeric mice that were obtained in the absence of the 
endogenous bcr allele [34]. This strategy was very useful for studying the leukemogenic potential of 
p190 BCR-ABL expressed under normal transcriptional control elements.  
 
In summary, transgenic models were first of its kind to validate the oncogenic potential of BCR-ABL 
and to support the expression of BCR-ABL as the prime initiating event for CML induction by p190 
BCR-ABL [29]. Furthermore, conditional models largely contributed to understand the course of 
human CML as well as to study CML leukemic stem cells. The applicability of such model lies in 
understanding the basis of initial events in BCR-ABL leukemogenesis. Since the expression of BCR-
ABL is restricted to primitive stem/progenitor cells compartment, the longer latency of disease 
development is evident. Furthermore, being the HSC/primitive cell initiated model, mechanistic 
studies downstream of BCR-ABL as well as the collaborating molecular abnormalities leading to 
blast-phase of disease could be studied in great details. It was using this inducible scl/p210 BCR-
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ABL transgenic murine model, that the studies from the group of Sengupta A. et.al. confirmed the 
role of BMI1 in collaboration with BCR-ABL to transform chronic phase lymphoid progenitors to 
induce serially transplantable B-ALL [35]. This model was also used to demonstrate that RAC2 
deficiency caused functional exhaustion of CML LSC pool in vivo [Sengupta A. Blood 2010]. 
Recently, studies from group of Huntly B. combined transgenic mouse model of CP-CML with mouse 
transposon-based insertional mutagenesis system for identifying the mechanisms of progression of 
CML. This study was first of its kind to functionally prove that BCR-ABL expression provides a 
selective pressure for a specific mutational event and associates with random events. This model 
system can thus be employed to identify random secondary mutations along with BCR-ABL 
[Giotopoulos G. J Exp Med. 2015]. 
 
The use of transgenic (conditional) models can thus play a major role in understanding secondary 
collaborating events in the progression of CML. However, generation of new founder transgenic mice 
every time, as well as BCR-ABL toxicity and silencing for establishing CML transgenic models, 




A murine bone marrow transduction approach was set up by Daley and colleagues with a retrovirus 
encoding p210 BCR-ABL in order to model CML [5]. Transduced cells were transplanted into 30 
lethally irradiated syngeneic recipients. 13 out of 30 (43%) transplanted mice developed 3 distinct 
hematological malignancies within 5 months after reconstitution: a CML-like myeloproliferative 
syndrome with a mean latency of approximately 9 weeks; ALL with a mean latency of approximately 
14 weeks; and a tumor containing macrophage cell types with a mean latency of approximately 16.5 
weeks [5]. Bone marrow from one of the affected mice was transplanted into lethally irradiated 
secondary recipients which also developed a CML-like syndrome [5].  
 
Kelliher and colleagues also transduced bone marrow cells from 5-FU treated mice with either v-abl 
or p210 BCR-ABL retroviruses and transplanted these into lethally irradiated mice. Half of the mice 
developed a myeloproliferative disease resembling chronic phase CML while the remaining animals 
developed pre-B-cell lymphomas  [36]. All 19 mice that received Abelson murine leukemia virus 
(Ab-MLV) infected cells succumbed 4-10 weeks later due to myelomonocytic leukemia and pre-B 
cell lymphoma while 11 out of 12 mice that received BCR-ABL transduced cells died 9-12 weeks 
post reconstitution due to myelomonocytic leukemia, granulocytic leukemia, and pre-B cell 
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lymphoma [36]. A great asset of this transduction model was that clonality could be assessed by 
making use of the unique integration sites as clonal markers.  
 
Follow-up studies by several groups in which transduction efficiencies were further improved led to 
retroviral transduction/transplantation models that resulted in a rapid induction of CML-like 
myeloproliferative disease (MPD) in 100% of the cases, possibly due to efficient BCR-ABL 
expression in appropriate target cells. This disease was characterized by increased granulocytosis, 
splenomegaly, dissemination to other organs (lung) and efficient secondary transplantations [37-40]. 
However, variability in viral titers still affected the reproducibility of such models. Also, the use of 
strong promoters to drive BCR-ABL expression hindered modeling of leukemia with a longer latency. 
The transduction/transplantation models prove to be more efficient as compared to transgenic mice 
in terms of the quick and simple approach that facilitate easy determination of clonality of leukemias, 
secondary trasnplations as well as to study collaborating events synergistic for BCR-ABL induced 
disease. Studies from Bousquet et al. showed that miR-125b overexpression independently induces 
lymphoid or myeloid leukemia as well as acts as a secondary event by accelerating the development 
of p210 BCR-ABL induced leukemia [41]. Studies from Chang et al. have highlighted the role of 
Vav3 as critical GEF in p190 BCR-ABL mediated activation of RAC GTPase and down-regulation 
of proapoptotic signals required for leukemogenesis [42]. Furthermore, Grb10 knockdown mice 
demonstrated that Grb10 is an important intermediate in BCR-ABL signaling cascade in vivo which 
is required for efficient induction of leukemia in mice [Illert A. Leukemia 2015]. Such model systems 
can therefore directly validate the signaling pathways activated by BCR-ABL critical to 
leukemogenesis. Although, current murine transduction/ transplantation models fail to mimic the 
longer latency of human CML and transplantable myeloid secondaries. Thus, it of utmost importance 




One of the earliest attempts to model human CML in immunodeficient mouse models dates back to 
the late ’70s where the BCR-ABL+ cell line K562 was injected into nude mice and which grew as 
solid vascularized tumors containing cells like those seen in the patient and in the cultures [43]. 
Similar observations with the K562 cell line were later reported by Carretto and colleagues [44].  
Sawyers and colleagues observed that cell lines and BM samples from patients with myeloid blast 
crisis CML could be transplanted into SCID mice by injecting the cells into a localized area, either 
by intraperitoneal (i.p.) injection or within the renal capsule [45].  Efficient engraftment and 
dissemination of leukemia was observed in BM and PB. Interestingly, differential growth in the 
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spleen was seen in these myeloid blast cells as compared to lymphoid cells. Engraftment of chronic 
phase CML patient samples was infrequent and only limited myeloid growth was observed [45].  
Sirard et al also provided evidence of engraftment of both normal and leukemic hematopoietic cells 
from CML patients in sublethally irradiated SCID mice without exogenous treatment of cytokines 
[46]. However, high cell numbers for transplantation, and infrequent and limited lymphoid as well as 
myeloid outgrowth was still a drawback in these SCID mice, perhaps due to residual innate immunity 
of this SCID mouse.   
 
Over the years, with the development of better immunodeficient models such as the severe combined 
immune deficiency (SCID) mouse model, transplantation of human normal and leukemic cells 
improved significantly, in particular of the lymphoid compartment. However, engraftment of myeloid 
(malignant) cells remained challenging and many researchers focused their efforts on developing a 
system that would permit efficient interactions between human cells and their microenvironment. A 
first model that attempted to re-create a human environment to allow long-term multilineage human 
hematopoietic activity was reported by McCune and colleagues by coimplantation of small fragments 
of human fetal thymus and fetal liver into immunodeficient SCID mice, although this model was not 
used to study myeloid transformation [47]. With the development of NOD-SCID mice with 
functionally defective lymphocytes and NK cells several groups successfully showed engraftment of 
mononuclear and CD34+ cells from PB of CML patients using lower cell numbers than those reported 
for SCID mouse models of CML [48-50]. One of the challenges in developing in vivo models for 
human CML that remained was that normal stem cells frequently outcompeted CP-CML stem cells. 
By identifying patients in which the in vitro long-term culture-initiating cells (LTC-ICs) were 
predominantly leukemic and by injecting those cells into NOD/SCID or NOD/SCID β2m-/- mice more 
consistent engraftment was seen for 5 months after transplantation [8].  At late time points, mice 
succumbed to endogenously derived thymomas, but no indication of progressive disease was evident 
indicating that this model only represented the chronic phase of the disease [8].  
 
The group of Connie Eaves presented a preleukemic in vivo model for CML by transducing primary 
human cord blood CD34+ cells with MSCV driven p210 BCR-ABL followed by transplantation into 
NOD-SCID and NOD-SCID  2-/- mice. Increased engraftment was observed with a reduction in B-
lineage output and enhanced production of erythroid and megakaryocytic cells [51]. However, only 
4 out of 28 mice displayed elevated WBC counts and/or gross splenomegaly with a latency of 5-6 
months. Although progression to BC-CML was not observed, these data clearly indicated that 
expression of BCR-ABL resulted in deregulated growth and differentiation which in some cases 
progressed to early stage disease.  
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Since BCR-ABL by itself appeared insufficient to induce leukemia in xenograft models, it has been 
proposed that additional pathways might be necessary to cooperate with BCR-ABL in the transition 
from CP-CML into BC-CML, such as the Wnt and Hedgehog pathways [16,52,53]. Alternatively, it 
has been observed that expression of the polycomb gene BMI1, which is implicated in normal and 
leukemic stem cell proliferation [54,55], is significantly higher expressed in patients with advanced 
disease than in patients with CP [56].  Therefore, we evaluated whether BMI1 could act as a 
collaborating factor together with BCR-ABL. We confirmed that co-expression of BMI1 and BCR-
ABL in human CB CD34+ cells is sufficient to induce transplantable leukemia in NOD/SCID mice 
[57]. The disease progressed to lymphoid blast crisis phase and serially transplantable B-ALL could 
be established  [57].  
 
Although the development of xenograft mouse models has allowed the ability to work with primary 
patient samples in vivo, the pathogenesis of CP-CML progressing into a BC-CML was still very 
difficult to model. And while in human retroviral transduction models a serially transplantable B-
ALL could be established, the development of myeloid malignancies in xenograft models remained 
rather challenging. Various phenomena could underlie these observations including residual host 
immunity in the xenograft models that were used, or possibly even more importantly the lack of a 
proper human microenvironment for sustaining human myeloid leukemias. 
 
Humanized mice models 
 
The most immune deficient mouse model till date is the IL2Rγ-/- mouse (NSG), which features the 
NOD/ShiLtJ background, the severe combined immune deficiency mutation (scid) and loss of the 
IL2 receptor gamma, and completely lacks T, B and NK cells. After its development, NSG xenograft 
transplantation models soon emerged as the gold-standard for accessing in vivo repopulation of HSCs 
as well as LSCs. However, in 2011 the group of Dominique Bonnet reported the failure of 
engraftment of 60-70% primary AML cells [58]. Importantly, these NSG mice remained rather biased 
towards lymphopoiesis, and normal or malignant myelopoiesis remained difficult to achieve. Despite 
the fact that these xenograft models are immune deficient and would tolerate a human graft, the 
absence of a human microenvironment might still prevent appropriate growth of human cells. Indeed, 
various growth factors are species-specific, and for instance, murine IL3 or GM-CSF fail to activate 
human receptors, which might, at least in part, explain the lymphoid bias. The group of Donna Hogge 
and Connie Eaves established NOD-SCID mice transgenic for human SCF, IL-3, and GM-CSF 
[59,60]. A number of AML samples that failed to engraft in the regular NOD-SCID mice could now 
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engraft in the human cytokine NOD-SCID mice. The group of Jim Mulloy then crossed these mice 
into the NSG background and also reported better engraftment of AML samples in NSG transgenic 
for hSCF, hIL-3, and hGM-CSF [61].  
 
Although these mouse xenograft models clearly hold promise, there are some potential pitfalls also. 
Since these are transgenic models and the human alleles are not knocked into their endogenous loci, 
expression levels might differ from the physiological levels, which might have important 
consequences for the normal self-renewal and differentiation programs. Possibly, this is tackled in 
the MYSTRG mice generated by the Flavell lab, in which 4 human cytokines are knocked into their 
respective mouse loci [62]. However, an appropriate niche obviously consists of more factors than 
just these cytokines. Direct interactions with the niche are not only important for normal HSCs but 
are also critical for LSCs [63]. For instance, N-cadherin mediates critical interactions between CML 
LSCs and their niche [64]. In fact, there is a continuous crosstalk between LSCs and their niche and 
in particular in the case of CML is has been documented that LSC gradually changes their niche so 
that it favors leukemogenesis [65,66].  Thus, an ultimate model in which human hematopoiesis and 
leukemogenesis might be studied is a model in which the niche is of human (malignant) origin as 
well. Richard Groen has described a humanized model using NSG mice in which ceramic scaffolds 
seeded with human mesenchymal stromal cells were implanted to generate a human bone marrow 
(huBM)-like niche  [67,68]. We have extensively studied our retroviral CB CD34+ BCR-ABL 
model within these humanized niche NSG mice as well, and our data indicate that BCR-ABL 
overexpression alone was sufficient to induce both AML and ALL, that could be serially 
transplanted. By comparing transcriptomes of leukemias derived from murine niches versus 
leukemias from the huBM-like scaffold (huBMsc)-based niches we observed striking differences 
in expression of genes associated with hypoxia, mitochondria, and metabolism. Efficient 
engraftment of blast-crisis CML patient cells was also observed whereby the immature blast-like 
phenotype was maintained in the human scaffold niche, but to a much lesser extent in murine niches. 
Thus, we have established human niche models in which the myeloid and lymphoid features of 
BCR-ABL+ leukemias can be studied in detail [Sontakke et al, Chapter 3]. Future studies will be 
aimed at evaluating whether CP-CML patient samples can also engraft in this model, and whether 
the chronic to blast crisis progression can be modeled as well. Recently, studies using tetracycline-
inducible transgenic murine model (under the control of scl gene) showed that the inflammatory 
environment (;especially increased production of pro-inflammatory cytokine IL-6), directly 
transform healthy stem/progenitor cells into ‘leukemic like’ progenitor cells. Thus, proposing that 
targeting non-mutated niche cells can hamper leukemic progression [Welner R. Cancer Cell 2015]. 
Therefore, humanized models can be applicable not only for studying species-specific interactions 
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of CML LSCs with niche but also such model system will serve as a unique platform to validate 




CML is one of the most studied and best understood hematological malignancies until now and has 
captivated the interest of several cancer stem cell enthusiasts to push the limit of drug discovery by 
further understanding the molecular mechanisms underlining this disease. Over the past 35 years, 
CML models have been developed and continuously improved, that have greatly aided in our 
understanding of the disease. With the establishment of a humanized niche model, it will be possible 
to further study and understand the crosstalk between leukemic cells and their environment in relation 
to the pathogenesis of CML. This should bring us a step closer to a complete understanding of the 
mechanisms by which BCR-ABL exerts its transformation potential, intrinsically within 




Apart from regenerative medicine, iPSC technology is also providing an excellent platform to model 
and study the pathophysiology of diseases such as myeloproliferative neoplasms including CML and 
PV. Carette J. and Pruszak J. et al. successfully reprogrammed the KBM7 BC-CML cell line into 
CML iPSCs [69]. Hu et al. reprogrammed MNCs from BM of CP-CML patient using non-integrating 
episomal vectors [70]. Although the DNA methylation pattern of CML-iPSCs was different from that 
of original CML samples, it was very similar to normal iPSCs, and human ES cells in terms of gene 
expression profile. However, the disease never progressed to BC phase probably due to lack of 
additional mutations. Later on, the group of Kurokawa generated CML iPSCs from imatinib sensitive 
CML patient samples [71]. Intriguingly, the CML-iPSCs were insensitive to imatinib, while CML-
iPSC-derived hematopoietic cells recovered the sensitivity to imatinib with the exception of 
CD34+38-90+45+ immature cells that remained resistant, possibly in line with what is observed in 
patients. A challenge that remains is that reprogramming of CML iPSCs results in epigenetic 
alterations different from what was observed in the original patient samples, and thereby also the 
characteristics of the iPSC CML cells. Despite this, iPCS provides an exciting novel technology with 
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Supplementary Table 1. Overview of in vivo CML models. 




driven by Eµ or 
promoter/enhancer of 
MPSV LTR. 
pre-B and T lymphomas 
(3/12 with EµVh vector), 
T lymphomas (1/3 with 
MPSV LTR vector). 
BCR-v-ABL possesses 
oncogenic capability in vivo.  
Synthetic BCR-v-ABL not 
similar to original hybrid 
protein. Increase embryonic 
lethality.  
[1] 
P190 BCR-ABL gene 
driven by delta 
metallothionein-1 
promoter. 
myeloid leukemia (2/8 mice) 
and 
lymphoid leukemia (6/8 
mice) between 10-58 days of 
birth.  
Follow up studies with 





P210 BCR-ABL gene 
driven by delta 
metallothionein-1 
promoter. 
T cell leukemia.  The tumorigenicity of P210 
BCR-ABL chimeric gene 
products is specific for the 
hematopoietic cells. 
[4] 
P210 BCR-ABL gene 
driven by the mouse tec 
promoter. 
ALL (2/5 founder mice 
developed),  
MPDs in transgenic progeny 
with 4-8 months of latency.  
Transgenic progeny of one 
founder mice exhibited 
MPD with fundamental 
features of CML. Secondary 
mice showed excessive 
proliferation of myeloid and 
megakaryocytic cells 
however succumbed to 




Tet-off system: tTA 
driven by the MMTV-
LTR promoter  
Lethal B-ALL developed in 
100% of mice within 3-11 
weeks on with-drawal of 
Tetracycline due to P210 
BCR-ABL1 expression. 
MMTV-LTR promoter 
directed expression of tTA 
to B220+ BM cells.  
Abolition of BCR-ABL1 
expression lead to apoptosis 
of leukemic cells and hence 
reversal of B-ALL 
phenotype. Reverted mice 
from one founder did 
succumb to ALL without 
BCR-ABL expression, 
possibly due to the 
acquisition of additional 
mutations.  
[6] 
Tet-off system: tTA 
driven by the SCL 
promoter  
Neutrophilia, leukocytosis 
and dissemination of 
myeloid cells into spleen, 
liver, lymph nodes within 
29-122 days upon 
tetracycline withdrawal due 
to P210 BCR-ABL1 
expression.  




recapitulates many features 
of human CP-CML. 
[7] 
Overexpression of BMI1 
by ubiquitin C promoter 
in a lentiral EGFP vector 
in BCR-ABL expressing 
CP-CML stem cells and 
Development of serially 
transplantable B-ALL with 
accumulation of 
BMI1/BCR-ABL+ B-cells 
Bmi1 synergizes with BCR-
ABL to transform chronic-
phase Scl/p210 B-lymphoid 






binary mouse model. 
after 16 weeks of 
transplantation.  
(MPPs) and imparts a 
proliferative advantage to 
induce serially 





E14 ES cells to create in-
frame fusion of P190 
BCR-ABL with exon 1 
of murine bcr in the 
presence or absence of 
the endogenous non-
rearranged bcr allele. 
bcr-ABL/bcr+ chimeric mice 
and 37/40 bcr-ABL/bcr- 
developed B-ALL. 
bcr-ABL fusion gene does 
not require endogenous bcr 




Mu BM transduced with 
retroviral construct of 
P210 BCR-ABL 
expressed under control 
of MPSV myeloid cell-
specific promoter. 
13/30 developed 3 distinct 
malignancies: CML, ALL 
and macrophage-like tumor 
Retrovirus mediated 
expression of P210 BCR-
ABL demonstrate murine 
model system for CML. 
[10] 
Mu BM of 5-fluorouracil 
(5-FU) treated mice 
transduced with v-abl or 
P210 BCR-ABL 
retrovirus. 
>90 % mice that received v-
abl or BCR-ABL transduced 
cells died due to 
myelomonocytic leukemia, 
granulocytic leukemia and 
pre-B cell lymphoma. 
Both BCR-ABL as well as 
activated v-abl can induce 
similar malignancies. 
Integration site analyses 
allowed evaluation of 
clonality.  
[11] 
Mu BM transduced with 
retroviral construct of 
P210 BCR-ABL under 
control of MSCV LTR 
promoter in the presence 
of SCF  
All recipients came down 
with disease and displayed 
markedly elevated WBC 
counts with granulocyte 
predominance. 
Induction of murine CML in 
100% of recipients with 4-6 
weeks latency.  
All secondaries succumbed 
to lymphoid neoplasms. 
[12] 
5-FU treated Mu BM 
cells transduced with 
retroviral construct of 
P210 BCR-ABL 
expressed under control 
of MSCV promoter. 
Elevated WBC counts; 
majority of which were 
granulocytes but also 
included myeloblasts and 
basophils.  
Induction of transplantable 
myeloproliferative disease 
resembling CML. 
Leukemic cells expressed 
excess IL3 and GM-CSF. 
[13;14] 
5-FU treated/untreated 
Mu BM cells transduced 
with retroviral construct 
of P210 BCR-ABL P190 
BCR-ABL and P230 
BCR-ABL expressed 
under control of MSCV 
promoter. 
CML-like syndrome when 
5-FU treated donor cells 
were used. 
Mixture of CML-like 
disease, B-ALL and 
macrophage tumors when 
non 5-FU treated donor cells 
were used. 
All 3 forms of BCR-ABL 
induce identical CML-like 
syndrome in mice but P190 
BCR-ABL had increased 




marrow cells with a 
retrovirus encoding 
p210 BCR-ABL together 
with the XZ-miR-125b 
over-expressing 
miR-125b or the control 
vector XZ were 
transplanted into lethally 
irradiated BALB/c 
recipient mice. 
50% of mice died of B-ALL, 
42% with MPN, and 8% of 
mixed (myeloid and 
lymphoid) leukemia when 
transplanted with miR-125b 
plus BCR-ABL–infected 
cells with median survival of 
21days as compared to 35 
days in BCR-ABL 
transduced control group.  
 
miR-125b accelerates the 
oncogenicity of BCR-ABL 
in transplanted mouse 
model. 
[16] 
B-ALL LDBM cells 
from specific gene-
> 90% of recipient mice 
developed B-ALL in 




deleted murine models 
or WT mice and UCB 
CD34+ were transduced 
with bicistronic 
vectors expressing EGFP 
and p190-BCR-ABL 
(MSCV-p190-
BCRABL) or only EGFP 
(MIEG3), then cultured 
with IL-7 and SCF. 
approximately 37 days 
characterized by B220dim+, 
CD19+, CD43+/dim B-cell 
progenitor population. 
Infiltration in other organs 
was also evident.  
leukemogenesis, 
proliferation and survival 




Method Phenotype of leukemia Features Refs 
Xenograft  
Nude mice 
Nude mice injected with 
K562 
K562 grew as solid 
vascularized tumors.  
Tumor cells were triphoid 
and retined human 
chromosome markers. 
[18] 
SIA-nu/nu mice were 
injected with leukemic 
cell lines and primary 
patient sample.  
K562 formed solid tumor at 
challenged site without 
metastatic spread with mean 
latency of 10 days.   
6/8 leukemic cell lines and 
5/18 primary neoplastic 
tumors induced serially 





BM samples of CP-CML 
and BC-CML as well as 
cell-lines; K562 and 
EM-2 were transplanted 
into CB-17 scid/scid 
mice. 
All mice injected with K562 
as well as EM-2 or primary 
CP-CML and BC-CML 
samples by IV or IP engraft 
to give myeloblasts in BM, 
blood and tumors in 
peritoneum. 
After initial growth in 
kidney capsule, myeloblasts 
were detected at varying 
levels in PB and BM. 
Human myeloid and 
lymphoid leukemia cell-
lines showed distinct growth 
patterns.  
Differences were also 
observed in engraftment of 
CP vs BC-CML primary 
patient samples. 
[20] 
BM or PB samples 
obtained from CP-CML 
and BC-CML patients 
were injected by IV into 
sublethally irradiated 
[400cGy] SCID mice. 
Exogenous cytokines 
PIXY321 or c-kit ligand 
was injected IP. 
CP-CML and BC-CML 
patient sample showed 1-
>10% engraftment with 30-
60 days latency in presence 
or absence of exogenous 
human cytokines.  
Multilineage engraftment 
and CD34+ cells were 
maintained for more than 60 
days after transplantation.  
First evidence that both 
normal and leukemic CP-





MNCs from apheresis 
material from CML 





CD34+ and CD34- cells 
were also used for BM 
engrafted studies.  
≥1-84% multilineage 
engraftment observed in BM 
in 76% mice and only 66% 
of mice showed 
16%predominantly T cell 
splenic engraftment.  CML 
like disease in BM and 
spleen. 39% ±5% leukemic 
engraftment in 25 mice 
having ≥ 9% BM 
engraftment was higher as 
compared to BCR-ABL 
engraftment in spleen.  
Higher engraftment in 
NOD/SCID mice using low 
cell dose compared to SCID 
mice.  
[22] 
MNCs or CD34+ 
enriched cells from BM 
or PB of 11 CP-CML 
25% of NOD/SCID 
recipients had 40-80% 
human cells where as only 3 
NOD/SCID mice allow 
greater engraftment and 
amplification of both normal 
[23] 
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% SCID mice contained 
similar levels. Further, 
engrafted human cells had 
high proportion of leukemic 
cells along with CD34+ 
cells.  
and leukemic cells as 
compared to SCID mouse 
model.  
BV173 and PB MN cells 
from CP, AP and BC 
CML patient samples 
were injected. 
Kinetics and extent of 
engraftment BP > AP > CP. 
Although according to 
growth rate BP > AP ≥ CP. 
Kinetics of BM repopulation 
are different for CP, AP and 
BC phase of CML. 
[24] 
9 CP-CML patient 
samples with 
predominant LTC-IC 
were transplanted into 
sublethally irradiated 
[350cGy] NOD/SCID 
and NOD/SCID β2m-/- 
mice. 
Consistent and durable 
engraftment was observed 
with reduced output of B 
cells and enhanced 
myelopoiesis with excessive 
production of erythroid, 
megakaryocytes and BCR-
ABL CD34+ expressing IL-
3, G-CSF transcripts. 
No progressive disease 
phenotype was observed 
marking CP-CML phase of 
the disease.  
[25] 
CB CD34+ cells were 
transduced with MSCV 
based retroviral 
constructs for BCR-ABL 
and transplanted 0.2 to 




NOD/SCID β2m-/- mice. 
BCR-ABL transduced cells 
produced increased ratio of 
myeloid to B-lymphoid cells 
with increase in erythroid 
and megakaryocytic cells. 
4/28 mice developed an 
increased WBC count and/ 
or splenomegaly after 5-6 
months latency.  
First ever model to describe 
the de novo generation of 
pre-leukemic cells by forced 
expression of BCR-ABL in 
human CD34+ CB cells. 
Primary CD34+ CB cells 
showed a rapid and 
persistent deregulation and 
erythroid and 
megakaryocytic biased 
differentiation in vivo with 
occasional progression to an 
early stage of CML. 
[26] 
CB CD34+ cells were 
transduced with MSCV 
based retroviral 
constructs for BMI1 and 
BCR-ABL and 
transplanted only 0.46 to 
0.38 million cells into 
each sublethally 
irradiated [3 Gy] 
NOD/SCID mice. 
4/8 mice succumbed to 
[CD34+CD19+] B-ALL in 
16-22 weeks on 
transplantation of CD34+ 
cells cotransduced with 
BMI/BCR-ABL and all 
secondaries came down with 
similar phenotypes within 8-
12 weeks.  
Coexpression of BMI1 and 
BCR-ABL in CB CD34+ 
cells is sufficient to induce 
transplantable B-ALL in 
NOD/SCID mice. 
[27] 
iPSC KBM7 cells were 
reprogrammed by 
retroviral transduction of 
OCT4, SOX2, c-MYC 
and KLF-4.  
Teratoma formation and 
imatinib resistance was 
observed.  
The process of 
reprogramming KBM7 cell-
lines readily abolished BCR-
ABL dependency which was 
restored by differentiation 
into hematopoietic lineage. 
[28] 
MNCs from BM of CP-
CML patient sample 
were cultured with 
human SCF, IL-3, IL-6 
and Flt3L for 2 days and 
transfected with 
episomal vectors by 
nucleofection. 
CP-CML iPSC lines 
generated exhibited features 
of pluripotent stem cells, 
exhibited complex karyotype 
and differentiated into 
hematopoetic lineages. 
Transgene free CML iPSC 
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While expression of BCR-ABL together with BMI1 in human CD34+ cells is sufficient to induce a 
serially transplantable lymphoid leukemia, myeloid leukemias are more difficult to establish in 
xenograft mice. Since NOD-SCID IL2R -/- (NSG) models are typically lymphoid biased, we 
hypothesized that extrinsic factors might dictate lineage fate. Using NSG mice in which ceramic 
scaffolds seeded with human mesenchymal stromal cells were implanted to generate a human bone 
marrow (huBM)-like niche we observed that, in contrast to the murine BM niche, BCR-ABL 
overexpression alone was sufficient to induce both AML and ALL, that could be serially transplanted. 
We compared transcriptomes of leukemias derived from murine niches versus leukemias from huBM-
like scaffold (huBMsc)-based niches which revealed striking differences in expression of genes 
associated with hypoxia, mitochondria and metabolism. Genes such as CDKN1C/p57, MYC but also 
endogenous BMI1 were highly upregulated in leukemic cells from the huBMsc. Efficient engraftment 
of blast-crisis CML patient cells was also observed whereby the immature blast-like phenotype was 
maintained in the human scaffold niche, but to a much lesser extent in murine niches. In conclusion, 
we have established human niche models in which the myeloid and lymphoid features of BCR-ABL+ 




Chronic myeloid leukemia (CML) is a stem cell disease characterized by the presence of the 
Philadelphia (Ph) chromosome due to a reciprocal translocation between chromosome 22 and 
chromosome 9 t(9;22).1-3 The resulting chimeric BCR-ABL gene encodes for a constitutively active 
oncoprotein, the BCR-ABL tyrosine kinase. The ABL protein when fused with BCR loses its property 
to shuttle between nucleus and cytoplasm and thus remains in the cytoplasm where it interacts with 
various proteins.4-8 This leads to downstream activation of several pathways like STAT5, MAPK, 
PI3K,  -Catenin and many more, leading to a disturbance of normal cellular functions. As a 
consequence transcriptional networks are deregulated resulting in prolonged survival, expansion of 
leukemic cells and hence progression to CML disease.9 It is clear that the BCR-ABL translocation in 
the most primitive hematopoietic stem cells (HSCs) is necessary and sufficient to initiate the Chronic 
Phase (CP) of disease.10,11 However, it needs collaborating events for maintenance and progression 
of CML to Accelerated Phase (AP) and further to the Blast Crisis phase (BC). One such collaborating 
factor is the polycomb group member BMI1. BMI1 is a negative regulator of the p16INK4/p19ARF 
locus and plays a critical role in maintaining self-renewal of normal and leukemic HSCs.12-17 Other 
pathways, such as the WNT and Hedgehog pathways, have also been implicated to play a role in 
maintenance of BC CML stem cells.18-21 A further understanding of the mechanisms involved in 
progression and maintenance of CML LSCs may lead to the development of better therapeutic 
strategies to eradicate residual therapy-resistant LSCs. 
 
Establishing xenograft models can be a good approach to study CML. Currently, NOD-SCID IL2R -
/- (NSG) xenograft models are considered to be the gold standard for evaluating engraftment of human 
haematological malignancies. However, this model has serious drawbacks since 30-40% of primary 
AML samples failed to engraft even in the most immune-compromised NSG model.22 Furthermore, 
engraftment of normal human CD34+ cells in NSG mice is lymphoid biased. Using retro/lentiviral 
systems to model human leukemias we frequently observe that while in vitro both myeloid and 
lymphoid transformation can be achieved upon expression of oncogenes such as MLL-AF9 or BCR-
ABL/BMI1, in vivo transformation is strongly biased towards ALL.16,23 In patients the BCR-ABL 
p210 oncoprotein can give rise to both myeloid and lymphoid leukemias, and the same is true for 
MLL-AF9 in paediatric leukemia patients. Together, these observations suggest that a specific human 
microenvironment might be necessary for engraftment and maintenance of self-renewal of myeloid 
leukemic stem cells. Since certain myeloid growth factors are often species-specific, the mouse niche 
is most likely not sufficient to provide the appropriate environment for human LSCs. 
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To develop in vivo models that more faithfully recapitulate human disease driven by the BCR-ABL 
p210 translocation we made use of a humanized niche NSG xenograft model in which ceramic 
scaffolds coated with human mesenchymal stromal cells (MSCs) were used to mimic the bone 
marrow microenvironment are implanted in NSG mice.24,25 Next we studied the engraftment and 
initiation of CML by cord blood (CB) CD34+ cells transduced with BCR-ABL with or without BMI1, 
as well as CML patient cells. Our data indicate that serially transplantable ALL and AML could be 
established in the humanized scaffold xenograft model. Differences between transcriptome profiles 
of BCR-ABL cells harvested from murine and human niches were analyzed, and thus we identified 
niche-specific BCR-ABL signatures.  
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Materials and Methods 
 
Primary cell isolations 
 
Neonatal CB samples were obtained after informed consent from healthy full-term pregnancies from 
the obstetrics departments of the University Medical Center in Groningen (UMCG) and Martini 
Hospital Groningen. Peripheral blood and bone marrow from untreated patients diagnosed with CML 
at the UMCG were studied after informed consent and protocol approval by the Medical Ethical 
Committee of the UMCG, in accordance with the Declaration of Helsinki. After ficoll separation of 
mononuclear cells, CD34+ cells were enriched using a magnetically activated cell-sorting CD34 
progenitor kit or automatically by using auto Macs (Miltenyi Biotech) as described previously1 and 
cryopreserved until further use.  
 
Retroviral transductions  
 
The murine stem cell virus (MSCV)-BMI1-internal ribosomal entry site (IRES2)- enhanced green 
fluorescent protein (EGFP) and MSCV-BCR-ABL-IRES2-truncated nerve growth factor receptor 
(tNGFR) retroviral vectors were cloned into MiGR1 and MiNR1 as previously described.2 MiNR1or 
MiNR1-BCR-ABL transduced cells were stained with anti-NGFR-phycoerythrin (PE) antibody 
(Becton Dickinson) for analysis. Transductions of CB CD34+ cells were performed as described 
previously.1  
 
Establishment of the humanized scaffold niche xenograft model and transplantations 
 
The ectopic bone model was established as described previously.3,4 Shortly, four hybrid scaffolds 
consisting of three 2–3mm biphasic calcium phosphate (BCP) particles loaded with human MSCs 
were implanted subcutaneously into NSG mice. In some experiments, two control scaffolds were 
implanted; one of which was loaded with MSCs, but exposed to 30 Gy of x-rays 24 hrs prior to 
implantation; the other was not loaded with cells. NSG female mice were anesthetized by isoflurane 
and four to six subcutaneous pockets were made and 1 scaffold was implanted per pocket. The 
incisions were closed using Histoacryl. Mice were treated with temgesic buprenorphine 0.1mg/kg 
body weight before surgery and housed in separate IVC cages. Seven weeks after scaffold 
implantation, mice were sub-lethally irradiated using 1 Gy 24 hours before the injection of transduced 
CB cells or CML patient cells. 500.000 cells were directly into the scaffolds or i.v. as indicated during 
primary as well as secondary transplantations. CD45 engraftment was analyzed by timely bleeding 
 64 
procedures (once in three weeks) and mice that had considerable engraftment and that showed signs 
of sickness were euthanized by cervical dislocation. Single cell suspensions were prepared from 
peripheral blood, bone marrow (2 femurs), spleen, liver and the tumour mass around the scaffolds 
and were analyzed by flow cytometry. The BCP scaffolds were stored in formalin and further 
embedded in paraffin for IHC. Genomic DNA extracted from these single cell suspensions was 




All antibodies were obtained from BD Biosciences and Bio Legend. The following clones were used: 
CD45 (HI30), CD271 (C40-1457), CD19 (HIB19), CD15 (HI98), CD11b (ICRF44), GPA (GA-R2), 
CD20 (2H7), CD34 (581), CD38 (HIT2), CD3 (UCHT1), CD117 (104D2), CD36 (CB38), CD71 (M-
A712), CD14 (HCD14) and CD33 (WM53). Cells were incubated with antibodies at 4˚C for 30 min. 
For blocking nonspecific binding to Fc receptors, cells were blocked with mouse and human anti-Fc 
antibodies for 10 min at 4˚C. All FACS analyses were performed on a FACS Calibur (Becton 
Dickinson) or LSR-II (Becton Dickinson) and data was analyzed using Flow Jo (Tree Star, Inc.). 




Ligation-mediated polymerase chain reaction (LM-PCR) was performed as previously described.5 
PCR products were analyzed on a 2% agarose gel, gel-purified using the QIAquick Gel Extraction 




Formalin-fixed, EDTA-decalcified paraffin-embedded scaffold sections were processed for staining 
with H&E (Klinipath) or used for immunohistochemical analysis as described previously.4 
Endogenous peroxidase activity was blocked with 0.3% H2O2 in methanol. For antigen retrieval, 
sections were boiled for 20 minutes in a citrate buffer, pH 6, and then blocked with 2% BSA+0.1% 
Tx in PBS for 60 minutes. Next, the slides were incubated overnight at 4°C with anti-CD45 (2B11 + 
PD7/26; DAKO), anti-CD20 (L26; DAKO), anti-CD34 (QBEnd10; Beckman Coulter) and anti-
CD38 (38C03; Neomarkers). Binding of the Ab was visualized using the PowerVision Plus detection 
system (Immunovision Technologies) and 3,3-diaminobenzidine (Sigma-Aldrich). The sections were 
counterstained with hematoxylin, washed, and subsequently dehydrated through graded alcohol, 
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cleared in xylene, and coverslipped. Images were captured using an Axiostar light microscope (Zeiss) 




For the LTC-IC assays, newly transduced cells were sorted on MS5 stromal cells in limiting dilutions 
from 10 to 500 cells per well in 96-well plates as described previously.1  Briefly, cultures were demi 
depopulated weekly and fed with new medium. After 5 weeks of culture, the wells containing 
cobblestone areas were scored, after which the medium from the wells was aspirated and replaced 
with methylcellulose-containing cytokines. After an additional 2 weeks of culture, wells were scored 
as positive or negative to yield the LTC-IC frequency. Stem cell frequencies were calculated using 




Genome-wide expression analysis was performed on Illumina (Illumina, Inc., San Diego, CA) 
BeadChip Arrays Sentrix Human-6 (46k probesets). Typically, 0.5-1 µg of RNA combined from three 
to five independent transduction experiments was used in labelling reactions and hybridization with 
the arrays according to the manufacturer’s instructions. Data was analyzed using the GenomeStudio 
v2011.1 Gene Expression Module v1.9.0 (Illumina, Inc.) and Genespring (Agilent, Amstelveen, The 




All values are expressed as means ± SEM. The student t test was used for all other comparisons. 





Mouse versus human extrinsic cues dictate transformation potential in BCR-ABL/BMI1-
induced leukemia in humanized xenograft models. 
 
We wished to evaluate human BCR-ABL-driven leukemogenesis in the murine BM niche in classical 
NSG xenotransplantation models and compare that to leukemogenesis in the presence of a humanized 
bone marrow microenvironment. For the first approach we injected leukemic cells intravenously (i.v.) 
into sublethally irradiated NSG mice and evaluated leukemia development initiated in the murine 
bone marrow niche. For the second approach we used a humanized model that is based on 
subcutaneous implantation of human BM-like scaffolds (huBM i.sc.), as described previously (Figure 
1A).24,25 
 
When cord blood-derived CD34+ cells were transduced with both BCR-ABL-IRES2-tNGFR and 
BMI1-IRES2-EGFP vectors and non-sorted cells were injected i.v. into NSG mice in order to 
generate leukemias that developed in the murine BM niche, we observed that within 16-25 weeks 
CD34+/CD19+ B-ALL developed in mice that were injected with CD34 transduced cells (Figure 1B), 
in line with what we observed previously.16 In the murine BM niche, only BCR-ABL/BMI1 double 
positive cells were able to generate leukemia, and infiltration of double positive ALL cells was seen 
in spleen and liver (Supplementary Figure 1A-B). No myeloid or erythroid cells expressing CD33, 
CD11b, CD15 or GPA were observed in leukemic mice. As controls, CB CD34+ cells transduced 
with MiNR1-IRES2-tNGFR and MiGR1-IRES2-EGFP empty vectors were used. These cells did 
indeed engraft, and outgrowth was CD19+ lymphoid biased, but no leukemia was observed and 
animals remained healthy throughout the experimental period (data not shown). In contrast to the in 
vivo data, double transduced BCR-ABL/BMI1 cells could be readily transformed along the myeloid 
lineage in vitro, in line with previously published data (data not shown).16       
 
Next, we injected non-sorted CB CD34+ cells transduced with BCR-ABL and BMI1 directly into 
huBM i.sc. In 11-21 weeks, 11 out of 13 mice developed tumours at the site of injection and data for 
all these 11 mice is summarized in Figure 1C, Table 1, and suppl. Fig 1C. In contrast to i.v. injected 
mice that all developed CD19+ B-ALL, in transcutaneous injected huBM i.sc. mice both CD19+ B-
ALL phenotypes and CD19- AML phenotypes were observed (Figure 1C, 1D, Table 1, data will be 
discussed in detail in Figure 2). When transduced cells were injected into empty scaffolds or scaffolds 
coated with MSCs that were irradiated with 30 Gy prior to implantation leukemia development was 
never observed, in line with previous observations,24 indicating that an intact functional human niche 
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is essential. Migration of cells to the murine BM was observed in 3 out of 11 transcutaneous-injected 
huBM (i.sc.) mice, typically with a lineage phenotype resembling that of the leukemic cells in the 
hBM scaffolds (Table 1). 
 
Secondary transplantations were performed in both the mBM (i.v.) and huBM (i.sc.) models, whereby 
huCD45+ BM cells were injected i.v. into secondary mice, or huCD45+ cells retrieved from one 
scaffold were i.sc. injected into 9 scaffolds in three secondary huBMsc mice (details will be discussed 
in Figure 3). Mice developed leukemia with a shorter latency in the i.sc. model compared to the mBM 
i.v. model, and secondary leukemias developed significantly faster than primary leukemias in both 
models (Figure 1E, Table 1).  
 
 
Figure 1. Mouse versus human extrinsic cues dictate transformation potential in BCR-
ABL/BMI1-induced leukemia in humanized xenograft models. A) BCR-ABL/BMI1 transduced 
but unsorted human CB CD34+ cells were injected either intravenously (mBM i.v.) or directly into 
the humanized scaffolds (huBM i.sc.) 7 weeks after MSC scaffold implantation. B) Induction of B-
ALL by BCR-ABL/BMI1 human CB CD34+ cells characterized by CD19/CD34 positive blasts 
derived from the murine bone marrow when cells were injected i.v. C) 5/5 i.v.-injected mice 
developed B-ALL whereas 2/11 huBM i.sc.-injected mice developed B-ALL and the remaining 9/11 
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huBM i.sc.-injected mice displayed an AML phenotype. D) Induction of CD19-positive B-ALL or 
CD19-negative AML by BCR-ABL single-positive human CB CD34+ cells in the humanized scaffold 
niche when cells were injected by huBM i.sc. E) Kaplan-Meier survival curves of primary and 
secondary mice from mBM i.v. and huBM i.sc. models displaying the differences in kinetics of 
leukemia development.  
 
BCR-ABL can induce lymphoid and myeloid leukemia in a human niche xenotransplant model 
without exogenous BMI1. 
 
As described above, non-sorted CB CD34+ cells transduced with BCR-ABL and BMI1 were injected 
directly into huBM i.sc and within 11-21 weeks, 11 out of 13 mice developed tumours at the site of 
injection. Whilst in i.v. injected mice BCR-ABL single positive leukemic clones were never 
observed, in the transcutaneous injected huBM i.sc. mice 13 out of 18 leukemic scaffolds contained 
BCR-ABL-single positive leukemias, while in the remaining 5 out of 18 huBM i.sc.-derived 
leukemias both BCR-ABL single positive as well as BCR-ABL and BMI1 double positive clones 
were detected (Table 1). Apparently, in a humanized microenvironment co-expression of exogenous 
BMI1 was not required to induce BCR-ABL-positive leukemia. 
 
Furthermore, the huBM i.sc. allowed for the development of a variety of phenotypes ranging from B-
ALL with aberrant expression of myeloid markers, to more erythroid- and myeloid-biased leukemias. 
For example, huBM scaffold 3 of mouse m5 (Figure 2A-E) developed semi-solid tumours that were 
white of colour. FACS analyses of these tumours indicated that all cells were BCR-ABL single 
positive and all expressed CD19 and CD38, while CD34, GPA and CD11b were not expressed 
(Figure 2A). Somewhat surprisingly, CD33, CD36 and CD15 expression was also detected (Figure 
2A). These data were confirmed by immunohistochemical analysis, which also confirmed the 
formation of human bone formation (Figure 2C, D, Supplementary Figure 2A). Infiltration of BCR-
ABL single cells was observed in different organs like BM, spleen and liver and these cells showed 
a similar marker expression as the cells engrafted in the huBM i.sc. (Supplementary figure 2B-D). 
MGG staining confirmed a lymphoblastic phenotype of these cells and hence we concluded that mice 
developed B-ALL with aberrant expression of certain myeloid antigens (Figure 2E). Similar results 




i.v.=intra venous injection; i.sc.=intrascaffold injection; B=clones expressing only BCR-ABL; 
BB=clones expressing BCR-ABL and BMI1; blue boxes indicate CD19+ B-ALL clones; green 
boxes indicate CD19- AML clones; pink boxes indicate coexisting B-ALL and AML clones. 
Numbers in last four columns indicate percentage huCD45 chimerism. 
 
In the huBM i.sc. mouse m1 the developing tumours were more compact and red (huBM scaffold 3) 
or green (huBM scaffolds 1 and 4) of colour, indicative of erythroid development and 
myeloperoxidase expression, respectively. These cells did not express CD19 but did express 
intermediate to high levels of GPA and CD33, with the highest expression of GPA in huBM scaffold 
3 (Figure 2F). In addition, tumours were harvested from i.sc.-injected mice in which both BCR-ABL 
single as well as BCR-ABL/BMI1 double positive leukemic clones were detected, like huBM i.sc. 
mouse m10 (Figure 2G). This mouse displayed an immature tumour phenotype as indicated by high 
expression of C-KIT and low expression of other myeloid markers. No differences in FACS 
phenotype were observed between BCR-ABL single and BCR-ABL/BMI1 double positive clones 
(Figure 2G). Moreover, the proportion of BCR-ABL to BCR-ABL/BMI1 cells was comparable to 
what was seen directly after transduction at day 5 prior to injecting cells (Supplementary Figure 2E), 
indicating that none of these populations had gained a proliferative advantage over the other. 














Sc1 Sc2 Sc3 Sc4 BM PB Sp LV 
mBM (i.v.) 1-5 wk16-25 na na na na 90-100 (BB) 88 (BB) 90-100 (BB) 90-98 (BB) 
2nd mBM (i.v.) 6-10 wk 16 na na na na 90-100 (BB) 80-90 (BB) 90-100 (BB) 85-98 (BB) 
huBM (i.sc.) 1 wk 14 B B B B 100 (B) 51 (B)   
huBM (i.sc.) 2 wk 14 B - B/BB - 77 (B)    
huBM (i.sc.) 3 wk 21 - - B -     
huBM (i.sc.) 4 wk 21 B/BB B/BB - -     
huBM (i.sc.) 5 wk 16 - B B - 65 (B) 6 (B) 58 (B) 60 (B) 
huBM (i.sc.) 6 wk 14 B - - -     
huBM (i.sc.) 7 wk 12 - - B -     
huBM (i.sc.) 8 wk 11 - - B - 1 (B)    
huBM (i.sc.) 9 wk 21 - B - -     
huBM (i.sc.) 10 wk 21 BB/B - BB/B -     
huBM (i.sc.) 11 wk 21 B - - - 1 (B)    
2nd huBM (i.sc.) from 5 5.1 wk 6 B B B  1 (B) 4 (B) 1 (B) 1 (B) 
2nd huBM (i.sc.) from 5 5.2 wk 6 B B B  2 (B) 2(B) 3 (B) 9 (B) 





Figure 2. BCR-ABL can induce lymphoid and myeloid leukemia in a human niche 
xenotransplant model without exogenous BMI1. A) Detailed FACS analyses of BCR-ABL 
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positive cells from Scaffold 3 of Mouse 5 indicating positive surface marker expression for CD19, 
CD38 and also for CD33, CD15. B) 16 week post-transplantation a tumour was detected at the site 
of injection. C) HE staining of B-ALL tumour scaffold demonstrating efficient bone formation. D) 
B-ALL tumour scaffold section stained by immunohistochemistry for CD45 demonstrated 
engraftment of CD45+ human cells. CD45neg cells were also observed suggesting the presence of 
endothelial cells forming a vascularized niche. E) MGG staining confirmed the lymphoblastic 
phenotype of BCR-ABL single positive cells. F) FACS analyses of BCR-ABL positive cells from 
Scaffold 1 and 3 of Mouse 1 indicating expression of GPA, CD71 and CD33 markers. The more 
reddish Scaffold 3 was also the most positive for GPA. G) FACS analyses of CD45 positive cells 
from Scaffold 1 of Mouse 10 indicated the presence of BCR-ABL as well as BCR-ABL/BMI1 
positive cells with positive expression of CD117 while other myeloid markers showed lower 
expression. 
 
BCR-ABL single expressing cells can induce serially transplantable ALL. 
 
In order to evaluate the self-renewing potential of BCR-ABL single positive leukemic clones we 
performed secondary transplantations. Cells harvested from huBM scaffold 3 of mouse m5 were 
transplanted into 3 sub-lethally irradiated NSG mice carrying hBM saffolds, such that 3 scaffolds 
were inoculated with 0.16 × 106 cells per scaffold, while 1 scaffold was left uninjected (Figure 3A). 
Large tumours were observed in all 3 secondary transplanted mice and within 6 weeks mice presented 
with overt leukemia (Figure 1D, 3E). All injected huBM scaffolds of all 3 secondary transplanted 
mice contained BCR-ABL single-positive cells. FACS analyses indicated that different clones had 
engrafted into individual scaffolds. Some scaffolds contained CD19, CD38 and CD33 positive 
comparable to their phenotype in primary mice, although expression of CD15 was lost (Figure 3B-
D, Supplementary Figure 3A). huBM scaffold 2 from mouse m5.1 displayed multiple clones that 
varied in tNGFR expression, suggesting different levels of BCR-ABL expression in these clones. 
Clones with intermediate levels of BCR-ABL expression were positive for GPA while clones with 
the highest expression of BCR-ABL did not express GPA but in contrast expressed high levels of 
CD19 (Supplementary Figure 3B and data not shown). Interestingly, huBM scaffold 4 from 2nd mR 
was in fact not injected, but developed leukemia presumably from migrating cells derived from the 
other injected scaffolds. Scaffold 4 also contained several clones differing in BCR-ABL expression 
with a concurrent presence or absence of CD19 (Supplementary Figure 3C). Infiltration of BCR-ABL 
single positive cells was also observed to some extend in BM, spleen and liver (Supplementary Figure 
3D-F), although chimerism levels appeared to be very low (Table 1).  
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To obtain further insight into the clonality of these different engrafting populations, we performed 
LM-PCR on cells harvested from primary as well as secondary huBM scaffolds. As shown in Figure 
3F, multiple bands were observed suggesting the coexistence of multiple clones. The positive internal 
control is indicated by the arrow. The clone indicated by the red asterisk was detected in both the 
primary and all secondary transplanted animals. Furthermore, multiple different other integration 
sites were observed in secondary leukemic mice, indicative for oligoclonal disease. Since a number 
of these clones were not detected in the primary mouse these data suggest the presence of quiescent 
clones in the primary leukemic cell population that were activated upon serial transplantation. 
Sequence analysis of the red asterisk-marked clone indicated that this was an integration site within 
the fourth intron of the MOB1B gene. Transcriptome analyses revealed normal expression of MOB1B 




Figure 3. Cells expressing only BCR-ABL can induce serially transplantable ALL. A) 
CD19/CD33 BCR-ABL positive cells from Scaffold 3 of primary Mouse 5 were transplanted into 
three sub-lethally irradiated humanized mice (3 Scaffolds injected with 0.16 × 106 cells/scaffold; 
same number of cells as injected in primary mice). B, C and D) FACS analyses of individual scaffolds 
of all 3 secondary mice indicated CD19/CD33 positive BCR-ABL positive cells. Scaffold 2 of Mouse 
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5.1 showed multiple clones varying in tNGFR/BCR-ABL expression. E) Enlarged tumours were 
observed in all 3 secondary transplanted mice. F) Clonal analyses of primary and secondary scaffolds 
by LM-PCR. The positive internal control is indicated by the arrow, and multiple other bands were 
observed suggesting the coexistence of multiple clones. The clone indicated by the red asterisk was 
detected in both the primary and all secondary transplanted animals.  
 
Molecular characterization of murine niche versus human niche derived cells. 
 
In order to understand differences between leukemic transformation potential between murine niche 
derived and human niche derived BCR-ABL single positive or BCR-ABL/BMI1 double positive cells 
we decided to perform Illumina microarray analysis. Gene expression profiles of primary BCR-ABL 
cells harvested from scaffolds (1st huBM i.sc.), BCR-ABL cells harvested from scaffolds from 
secondary transplanted mice (2nd huBM i.sc.) as well as primary BCR-ABL/BMI1 cells harvested 
from murine BM and spleen (1st mBM/SP) were compared. 577 probesets were significantly 
upregulated in the huBM i.sc. derived leukemic cells compared to the mBM/Spleen-derived cells, 
while 458 probesets were downregulated (corrected p value<0.01 with Bonferroni multiple testing 
correction, >3 fold differentially expressed, Supplementary Table 2). These data indicate that 
significant differences existed in transcriptome signatures between leukemias that developed in the 
mBM versus huBM scaffold niches. The top differentially expressed genes are shown in the 
supervised cluster analysis in Figure 4a, indicating that the 1st huBM i.sc. sample clustered tightly 
together with the eight 2nd huBM i.sc. samples, while all three 1st mBM/Spleen samples clustered 
together, away from all huBM i.sc. samples.  Gene ontology (GO) analyses indicated that the huBM 
i.sc. overexpressed genes were significantly (FDR<1) enriched for processes such as purine 
nucleoside binding, apoptosis and mitochondrion. Genes upregulated in mBM-derived leukemias 
were significantly (FDR<1) enriched for GO terms methylation and histone core related genes (Figure 
4b). GSEA analysis indicated that huBM scaffold-derived leukemias were enriched for MYC targets 
and hypoxia signatures, suggesting that BCR-ABL cells derived from the humanized scaffold display 
differences in MYC dependency and hypoxic state as compared to mBM-derived leukemias (Figure 
4c). A number of selected GO terms for genes upregulated in huBM scaffold-derived leukemias are 
shown in Figure 4d and Supplementary Figure 4. Interestingly, p57, and MYC were some of the 
significantly overexpressed secreted proteins in huBM scaffold-derived leukemias. Another 
interesting observation was that endogenous BMI1 was overexpressed in BCR-ABL positive cells 
derived from humanized scaffolds, possibly explaining why exogenously overexpressed BMI1 is not 
required as is the case for leukemias that develop in the murine BM niche. Illumina data were 
validated by independent Q-PCR analyses (Figure 4e). Together, these data indicate that the 
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important differences in transcriptome signatures exist between BCR-ABL leukemias that develop in 




Figure 4. Transcriptome profiling of leukemic cells derived from murine i.v. models versus 
huBM i.sc. models. a) Gene expression profile of BCR-ABL positive cells harvested from a primary 
huBM i.sc. m5 (Scaffold 3), 8 secondary huBM i.sc. scaffolds (from m5.1, m5.2 and m5.3) as well 
as BCR-ABL/BMI1 positive cells harvested from BM and spleen (2x) from primary i.v. injected 
mice. A supervised hierarchical clustering analyses of differentially expressed genes is shown 
(differentially expressed genes were determined by using a corrected p value<0.01 with Bonferroni 
multiple testing correction, and >3 fold difference in expression levels, Supplementary Table S1). 
Primary and secondary huBM i.sc. samples clustered together, away from all 3 primary i.v. injected 
samples. BMI1, CDKN1C/p57, and MYC were some of the interesting candidate genes upregulated 
in huBM i.sc. 1st and 2nd scaffold derived samples. b) Gene Ontology (GO) analyses on genes up- or 
downregulated in huBM i.sc.  (human) niche derived cells versus i.v. injected murine niche-derived 
samples (>3 fold in i.sc. versus i.v. samples, p-value of ≤ 0.01). c) GSEA analyses on i.sc. versus i.v. 





Validation of Illumina data by real time PCR indicating expression of endogenous BMI1, p57 and 
MYC relative to the house-keeping gene RPL27. Experiments were performed in triplicate. 
 
Primary Blast Crisis (BC)-CML cells can engraft in the huBM scaffold mouse model and induce 
a fatal myeloid leukemia within 16 weeks post transplantation.  
 
To determine whether the humanized niches could support chronic myeloid leukemia (CML) we 
injected a primary patient BC-CML sample i.sc. in huBM scaffold mice. We inoculated mice with 
0.45 × 106 primary BC-CML CD34+ cells per mouse (150,000 per huBM scaffold) (Figure 5A). We 
observed that all three injected mice developed tumours within 16 weeks post-transplantation. 
Macroscopic evaluation of these tumours showed compact, well vascularised tumours that were green 
of colour (Figure 5B). FACS analyses indicated that all engrafted cells were positive for huCD45 as 
well as for myeloid markers like CD33, CD11b, CD14, and CD38 (Figure 5C). Infiltration of myeloid 
cells was observed in mouse BM, spleen and liver (Supplementary Figure 5A-C). FACS phenotypes 
of the original patient sample at diagnosis were compared to cells harvested from the human scaffold 
as well as from murine niches such as the BM, spleen and liver. We observed that cells in the mBM 
niche clearly displayed a more differentiated phenotype in terms of a higher proportion of cells 
expressing the markers CD11b, CD14 and CD15 while a lower proportion of cells expressed CD34 
(Figure 5C, F). In contrast, the phenotypic pattern of the leukemic cells derived from the huBM 
scaffold closely resembled the original patient phenotypic pattern of expressed markers and in 
particular CD34 percentages were quite comparable (Figure 5C, F). Morphological analyses by MGG 
staining confirmed the immature phenotype of scaffold-harvested cells as compared to murine BM-
harvested cells (Figure 5D). FACS analyses results were further confirmed by immunohistochemistry 
(Figure 5E).  
 
To functionally compare the self-renewing potential of cells harvested from murine BM niche with 
those retrieved from the human niche in the huBM scaffolds, we performed LTC-IC assays on these 
cells. CD34+ and CD34- cells were sorted and plated in limiting dilution and were scored after 5 
weeks. No cobblestone area forming cells (CAFCs) were detected at week 5 in CD34+ or CD34- 
isolated from murine BM harvested cells (Figure 5G), and only differentiated macrophages could be 
observed (data not shown). In contrast, CAFCs could readily be detected in cultures initiated with 
CD34+ cells isolated from the huBM scaffold harvested cells, with an LTC-IC frequency of 1 in 323 
+/-115 (Figure 5G). Thus, these results suggest that self-renewal of LT BC-CML LSCs was 
maintained in the context of a humanized BM niche. 
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Finally, Q-PCR analyses was performed on BC-CML samples harvested from the mouse BM and 
human scaffold niches, and similar as observed in our BCR-ABL retroviral overexpression models, 
a significantly increased level of endogenous BMI1 was observed in cells derived from human 
scaffolds (Figure 5H). 
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Figure 5. Primary BC-CML cells can engraft in the huBM-Scaffold mouse model and induce a 
fatal myeloid leukemia within 16 weeks post transplantation. A) Myeloid BC-CML patient 
sample 2007-048 was injected in 3 scaffolds and 1 scaffold was left uninjected in 3 different 
humanized mice. B) All 3 injected mice developed enlarged greenish tumours within 16 weeks post-
transplantation. C) Detailed FACS analyses of CD45+ engrafted cells derived from humanized 
scaffolds as well as from the murine BM. CD34 was higher expressed in cells retrieved from the 
human scaffold while CD15, CD11b and CD14 were higher expressed in cells derived from the 
murine BM. D) MGG staining indicated a more immature phenotype of scaffold-harvested cells as 
compared to more differentiated cells from the murine BM. E) BC-CML tumour scaffold sections 
stained by immunohistochemistry confirmed the expression of CD34, CD38 and CD45 and not CD20 
(upper panels 5x and lower panels 40x magnification). F) FACS phenotypes of the original patient 
sample at diagnosis were compared to harvested cells from human scaffold as well as murine BM, 
spleen and liver. G) LTC-IC assay on CD34 positive and negative cells harvested from humanized 
scaffolds or the murine BM in limiting dilution. H) Validation of endogenous BMI1 expression by 
qPCR in BC-CML cells derived from human scaffolds compared to murine BM niche relative to the 




Despite many advantages of various xenotransplantation mouse models for human BCR-ABL 
positive leukemias that have been developed till date, faithful recapitulation of myeloid phenotypes 
and efficient maintenance of long-term self-renewal of CML LSCs has remained challenging. One of 
the fundamental drawbacks of currently available mouse models is the absence of a human 
microenvironment that would potentially provide species-specific cytokines, growth factors and 
adhesion molecules that are essential for self-renewal and myelopoiesis. Here we used our previously 
developed humanized mouse model that provides a human BM-like scaffold-based (huBM i.sc.) 
microenvironment in which human BCR-ABL positive myeloid and lymphoid leukemias can be 
studied in detail. 
 
Various retro/lentiviral models have been established to model human myeloid and lymphoid 
leukemias, and while in vitro BCR-ABL or MLL-AF9 oncogenes (either alone or in combination 
with other hits) could induce transformation along myeloid or lymphoid lineages, in vivo 
transformation was always heavily lymphoid biased and in vivo myeloid transformation has been 
much more difficult to achieve in NOD-SCID based xenograft models, including the NSG mice 
16,23,28. Furthermore, a significant number of primary AML samples does not engraft in the NSG 
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mouse model, again pinpointing to the notion that a niche that allows self-renewal of myeloid 
(malignant) clones is not provided for in the NSG mouse.22 NOD/SCID-3/GM/SF mice engineered 
to produce human IL3, GM-CSF and SF were generated by the Eaves lab, which resulted in enhanced 
terminal myelopoiesis of transplanted human low-density cells isolated from BM or fetal liver, but at 
the same time in reduced numbers of primitive cells in the bone marrow 29. These mice were also 
described to allow engraftment of AML patient samples that had failed to engraft normal NOD/SCID 
mice, but were comparable to engraftment levels achieved in NOD-SCID 2-/- mice.30 The Mulloy 
lab then generated NOD-SCID IL2R -/- (NSG) mice expressing IL3, GM-CSF and SF and enhanced 
engraftment of pre-leukemic myeloid cell cultures as well as of primary human AML samples was 
achieved, although other human niche-specific factors might still be missing.31 We made use of a 
humanized mouse xenograft model that harbours a human BM-like niche in order to provide an 
appropriate “home’’ or microenvironment for the engraftment of human leukemic cells. Previous and 
ongoing studies have indicated that this huBM i.sc. based xenograft model allows efficient 
engraftment of patient-derived multiple myeloma cells,24 T-ALL,25 and we have also observed that 
AML patient samples efficiently engrafted in this humanized niche xenograft mouse model as well 
(32 and Antonelli, Groen and Schuringa, manuscript submitted). Here, we describe that this 
humanized niche model also allows for BCR-ABL-driven myeloid and lymphoid disease, in contrast 
to the NOD-SCID/NSG mouse in which exclusively CD19+ B-ALL was observed upon 
transplantation of transduced CB CD34+ cells (current study and 16). Also, we find that primary 
CD34+ CML patient cells can efficiently engraft in this xenograft model, whereby stemness is much 
better preserved in the human environment as compared to the mouse environment. Interdependence 
of BCR-ABL LSCs and the BM niche has been thoroughly investigated. Recently published data by 
Zhang and his colleagues show decreased expression of CXCL12 by BM stromal cells in CP-CML 
and there is also evidence to show that BCR-ABL-induced remodeling of BM niches can contribute 
to CML pathogenesis.33,34 In the current study we made use of normal MSCs isolated from healthy 
BM, but it will be very interesting to analyze whether MSCs isolated from CML patients would 
further improve the huBM i.sc. xenograft model. 
 
Our previous studies in NOD-SCID/NSG xenograft mice without human BM niches indicated that 
CB CD34+ cells transduced with BCR-ABL were not able to induce leukemia as a single hit 16, in 
line with data published by others.35 Only when additional hits were provided, such as co-expression 
of BMI1, a serially transplantable CD19+ B-ALL could be induced.16 Possibly, BMI1 was required 
to bypass (oncogene-induced) senescence, and also in mouse models BMI1 was shown to reprogram 
BCR-ABL+ lymphoid progenitors into B-ALL-initiating cells.17 In the huBM i.sc. xenograft model 
that we present here, transformation was achieved with both BCR-ABL-only expressing cells as well 
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as with cells that expressed both BCR-ABL and BMI1. Apparently, exogenous BMI1 is not an 
absolute requirement to allow transformation of human CB CD34+ cells transduced with only BCR-
ABL. Interestingly, when we compared transcriptome differences between leukemias derived from 
the murine BM niche with leukemias derived from the huBM scaffold niches, we observed that 
endogenous BMI1 was strongly upregulated in the human BM niche. Apparently, the human BM 
niche can provide for factors that induce BMI1 expression, which might include activation of SALL4 
or the Sonic Hedgehog pathway, which both have been show to be able to induce BMI1 
expression.36,37 Another intriguing observation is that BCR-ABL transduced CB CD34+ cells 
proliferated less fast in in vitro stromal co-cultures when human MSCs were used instead of MS5 
murine bone marrow stromal cells (Supplementary Figure 6A-B). Although further studies are 
required, these data might suggest that oncogene-induced senescence is not as quickly induced in 
BCR-ABL transduced CB CD34+ cells when cultured on human MSCs, possibly due to the high 
levels of BMPs and TGFs that are secreted by these MSCs. 
 
Finally, striking differences were observed between transcriptomes of leukemic cells derived from 
murine BM niches versus leukemic cells derived from the huBM scaffold niches, including in genes 
associated with hypoxia signalling, mitochondria and metabolism. The top differentially expressed 
gene there was enrichment for cell cycle inhibitors like CDKN1C/p57, and hypoxic signature-related 
genes were also enriched in the humanized microenvironment which have been show to contribute to 
stemness of HSCs/LSCs.43-47 Other upregulated factors in the human niche included MYC, and it will 
be interesting to identify the molecular mechanisms via which the human environment can impose 
the observed transcriptome changes in future studies. In conclusion, we describe here a huBM i.sc. 
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Supplementary Figure S1. mBM i.v. versus huBM i.sc. xenograft mouse models. A and B) 
Infiltration of BCR-ABL/BMI1 cells in spleen and liver when non-sorted cells were injected by i.v. 
Leukemia was characterized by CD19/CD34 positive blast cells as indicated by FACS analyses. C) 
Progressive increase in tumour volume of i.sc. injected mice over time in days. [NOTE: M10 had 
progressive increase in tumour volume for Scaffold 2; however, cells harvested were not sufficient 
for further analyses. M5 was sacrificed on basis of greater than 30% engraftment of CD45+ cells 





Supplementary Figure S2. huBM i.sc.-initiated BCR-ABL single positive cells induced ALL and 
AML. A) Immunohistochemistry staining for CD20, CD45 and CD38 indicating positive expression. 
CD34 showed negative expression. B, C and D) Infiltration of BCR-ABL single positive cells was 
observed in murine BM, spleen and liver. E) Transduction efficiency of BCR-ABL/BMI1 CB CD34+ 





Supplementary Figure S3. BCR-ABL as a single hit can induce a serially transplantable ALL 
in huBM i.sc. models. A) Loss of CD15 marker expression on secondary transplantation. B) Scaffold 
2 of m5.1 displayed BCR-ABL bright clone positive for GPA expression. C) Uninjected scaffold 4 
of m5.3 demonstrated similar FACS phenotypes in terms of CD19 positive expression. D, E and F) 
Infiltration of BCR-ABL single positive cells observed in murine BM, spleen and liver of all 3 




Supplementary Figure S4. Gene Ontology analyses on differentially expressed genes between 
muBM i.v. versus huBM i.sc. models. a-i) Overview of various genes specifically expressed in 










Supplementary Figure S5. Self-renewal of a BC-CML patient sample can be better maintained 
using the huBM i.sc. model. A-C) Detailed FACS analyses of BC-CML cells derived from murine 





Supplementary Figure S6. Expansion of CB CD34+ BCR-ABL transduced cells on human 
MSCs versus murine MS5. A) Proliferation of CB CD34+ BCR-ABL cells on MS5 showed 
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excessive proliferation as compared to that on human MSC. B) CAFCs observed on murine MS5 
versus human MSC at day 17. 
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The Warburg effect is probably the most prominent metabolic feature of cancer cells, although little 
is known about the underlying mechanisms and consequences. Here, we set out to study these features 
in detail in a number of leukemia backgrounds. The transcriptomes of human CB CD34+ cells 
transduced with various oncogenes, including BCR-ABL, MLL-AF9, FLT3-ITD, NUP98-HOXA9, 
STAT5A and KRASG12V were analyzed in detail. Our data indicate that in particular BCR-ABL, 
KRASG12V and STAT5 could impose hypoxic signaling under normoxic conditions. This coincided 
with an upregulation of glucose importers SLC2A1/3, hexokinases and HIF1 and 2. NMR-based 
metabolic profiling was performed in CB CD34+ cells transduced with BCR-ABL versus controls, 
both cultured under normoxia and hypoxia. Lactate and pyruvate levels were increased in BCR-ABL-
expressing cells even under normoxia, coinciding with enhanced glutaminolysis which occurred in 
an HIF1/2-dependent manner. Expression of the glutamine importer SLC1A5 was increased in BCR-
ABL+cells, coinciding with an increased susceptibility to the glutaminase inhibitor BPTES. Oxygen 
consumption rates also decreased upon BPTES treatment, indicating a glutamine dependency for 
oxidative phosphorylation. The current study suggests that BCR-ABL-positive cancer cells make use 






Chronic myeloid leukemia (CML) is a hematological stem cell malignancy mediated by the BCR-
ABL translocation between chromosome 9 and 22, t(9;22)(q34;q11) resulting in the Philadelphia 
chromosome in multipotent hematopoietic stem cells (HSC) [1-3]. The chimeric BCR-ABL gene 
encodes for the constitutively active tyrosine kinase oncoprotein BCR-ABL, which remains in the 
cytoplasm and can activate distinct intracellular signaling pathways that confer impaired 
differentiation, enhanced survival and a proliferative advantage [4-9]. Moreover, the BCR-ABL 
oncoprotein mimics growth factor signaling pathways that can promote cell proliferation further 
regulating cell metabolism [10]. Yet, little is known about the mechanisms by which BCR-ABL 
signaling impacts on bioenergetic and biosynthetic needs of cancer cells. 
 
Hypoxia inducible factors 1/2  (HIF1/2) act as transcription factors that are stabilized under hypoxic 
conditions. HIF1 has been characterized as an important factor controlling cellular metabolism, while 
the role of HIF2 remains less clear [11,12]. Previously, we identified HIF2 as a downstream target of 
STAT5 and observed elevated glucose uptake in STAT5 activated HSCs [13]. Several genes 
associated with glucose metabolism were upregulated by STAT5 in an HIF2-dependent manner, 
including SLC2A1 and GYS2 [13]. Under hypoxia, it has been shown that HIF1 regulates pyruvate 
dehydrogenase kinase (Pdk2/4) thus shunting entry of pyruvate into the tricarboxylic acid cycle 
(TCA), resulting in enhanced lactate production in quiescent HSCs [14]. Furthermore, Yu et al. have 
shown that a PTEN-like mitochondrial phosphatase, Ptpmt1 primes the switch to mitochondrial 
oxidative phosphorylation to support the energy demands in differentiating HSCs [15]. These studies 
highlight two distinct metabolic programs in quiescent and actively cycling normal HSCs. Apart from 
normal HSCs, HIF1 and HIF2 has also been associated with survival maintenance of  primary AML 
and CML leukemic stem cells (LSCs) [16-18]. Recently, imatinib resistance in BCR-ABL cells was 
correlated with increased expression of HIF1 which resulted in metabolic reprogramming by 
increasing glycolysis at the expense of a reduced glucose flux in the TCA pathway and pentose 
phosphate pathway (PPP) [19]. However, in general it has been proposed that imatinib might not 
completely block the de novo synthesis of purines and pyrimidines or fatty-acid synthesis needed for 
actively proliferating cells [20,21]. Also, it is plausible that CML cells can still be dependent on 
alternative sources of energy as well besides glucose.  
 
Glutamine, being the most abundant amino acid in the human plasma, has been shown to be essential 
for boosting mitochondrial metabolism in c-MYC transformed or IDH mutant AML [22-24]. 
Intriguingly, Le et al. have shown glucose-independent mitochondrial oxidative phosphorylation 
 96 
under hypoxic conditions in the presence of glutamine in P493 cells, a human B cell Burkitt 
lymphoma cell-line [25]. Hence, apart from being the obligate nitrogen donor for purine and 
pyrimidine synthesis, glutamine might play an important role in anaplerosis if it is either oxidized to 
form succinate or if it follows reductive carboxylation for generating citrate under hypoxia [26,27]. 
In the current study, we combined transcriptome and metabolome profiling in order to understand 
how oncogenes would impact on the metabolism of leukemic cells. Our data indicate that BCR-ABL 
could impose hypoxic signaling under normoxic conditions, coinciding with an upreglation of 
glucose importers SLC2A1/3, hexokinases and HIF 1 and 2. NMR-based metabolic profiling revealed 
a strong upregulation of lactate and pyruvate in BCR-ABL expressing cells even under normoxia, 
coinciding with enhanced glutaminolysis which occurred in a HIF1/2-dependent manner via 
enhanced glutamine import. The current study suggests that BCR-ABL-positive cancer cells make 
use of enhanced glutamine metabolism to maintain TCA cell cycle activity in glycolytic cells. 
 
Materials and methods 
 
Primary cell isolations 
Neonatal cord blood (CB) was obtained from healthy full-term pregnancies after informed consent in 
accordance with the Declaration of Helsinki from the obstetrics departments of the University 
Medical Centre Groningen (UMCG) and Martini Hospital Groningen, Groningen, The Netherlands. 
Donors were informed about procedures and studies were performed with CB by an information sheet 
that was read and signed by the donor, in line with regulations of the Medical Ethical Committee of 
the UMCG. All protocols were approved by the Medical Ethical Committee of the UMCG. After 
ficoll separation of mononuclear cells, CD34+ cells were enriched using a magnetically activated cell-
sorting CD34 progenitor kit or automatically by using auto Macs (Miltenyi Biotech) as described 
previously and cryopreserved until further use. Chronic phase (CP) (n=6) and Blast Crisis (BC) 
chronic myeloid leukemia (BC CML) blasts (n=1, #1) from the peripheral blood cells from untreated 
patients with the t(9;22) translocation, as well as an AML sample  (n=1, #2, FLT3-ITD, NPMwt, 
IDH1 R132H, t(3;5), +8[10]) were obtained and studied after informed consent in accordance with 
the Declaration of Helsinki, and the protocol was approved by the Medical Ethical Committee of the 
UMCG. Donors were informed about procedures and studies performed with AML cells by an 
information sheet that was read and signed by the donor, in line with regulations of the Medical 
Ethical Committee of the UMCG. In all cases, mononuclear cells were isolated by density gradient 
centrifugation and CD34+ cells were stained using CD34-PE antibody (BD Biosciences) and selected 
by sorting on a MoFLo (DakoCytomation) and used in coculture experiments. AML and CP/BC CML 
co-cultures were expanded in Gartner’s medium supplemented with 20ng/mL interleukin 3 (IL-3; 
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Gist-Brocades), granulocyte-colony stimulating factor (G-CSF; Rhone-Poulenc Rorer) and 
thrombopoietin (TPO; Kirin).  
 
Retroviral and lentiviral transductions 
 
The murine stem cell virus (MSCV)-BCR-ABL-internal ribosomal entry site (IRES2)- truncated 
nerve growth factor receptor (tNGFR) retroviral vector was cloned into MiNR1 as previously 
described [28]. Transduction of CB CD34+ cells was performed and transduced cells stained with 
anti-NGFR phycoerythrin (PE) antibody (Becton Dickinson) for analysis as described before [29]. 
For shRNA silencing, a lentiviral vector expressing a short hairpin against HIF1a was made by 
cloning the hairpin sequence from pSuper-puro-HIF1a1470 (which was a kind gift from Daniel 
Chung, Massachusetts general hospital, Boston, Massachusetts) into the pLVUT vector [30]. A short 
hairpin sequence against HIF2a was constructed by cloning the hairpin sequence from pRetro-Super-
HIF2a (obtained from Addgene, addgene number 22100) into the pLVUT vector. A control vector 
was made by cloning a hairpin against firefly luciferase into the pLVUT vector. Viral particles were 
generated and lentiviral transductions were performed as described before [31].  
 
Cell culture and treatment 
 
CB CD34+ transduced BCR-ABL positive cells with/without shHIF1 and shHIF2, normal CB CD34+ 
cells as well as K562 cell-lines (obtained from the American Type Culture Collection ATCC, 
Manassas, USA) cultured at density of 0.3 x 106 cells per ml in 24 wells tissue culture plate for 30-
50 days under normoxia (21% O2) either in HPGM with c-KIT, Flt3, TPO ligand for primary CB 
CD34+ cells or in IMDM along with 10% FCS and 1% PS for cell-lines. Day 19 CB CD34+ as well 
as BCR-ABL CB CD34+ cells were cultured under hypoxia (1% O2) for 24 hours and used for NMR 
analyses as described below. For BPTES sensitivity studies, CB, CB BCR-ABL as well as K562 cells 
were treated with DMSO control and 20µM and 40µM of BPTES and further used for Seahorse 
analyses.  
 
RNA isolation and real-time PCR 
 
Total RNA was isolated using the RNeasy Mini kit (Qiagen, Venlo, The Netherlands) according to 
the manufacturer’s instructions. The real-time RT-PCR was performed using the iScriptcDNA 
synthesis kit (Bio-Rad, Veenendaal, The Netherlands) with 0.5-1µg of total RNA and qPCR 
performed using SsoAdvanced SYBR green supermix (Bio-Rad) in a CFX Connect thermocycler 
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(Bio-Rad). Primers used and optimized PCR conditions were used as mentioned before [31]. 
Ribosomal protein like (RPL) 27 expression levels were used to calculate relative expression levels 




Most transcriptome data used in this study was published previously including CB CD34+ cells 
transduced with MLL-AF9 [32], FLT3-ITD [33], NUP98-HOXA9 [34], STAT5A [30,35-37] and 
KRASG12V [38] while new data was generated for CB CD34+ cells transduced with BCR-ABL which 
is included in Supplementary Table 1. Genome-wide expression analysis was performed on Illumina 
(Illumina, Inc., San Diego, CA) BeadChip Arrays (Illumina HumanHT-12 v4 Expression Beadchips 
(47K probesets)). Typically, 0.75 µg of cRNA from two independent transductions was combined 
and used in labelling reactions and hybridization with the arrays according to the manufacturer’s 
instructions, and two independent experiments were performed. Data was analyzed using 
GenomeStudio V2011.1 Gene Expression Module v1.9.0 (Illumina, Inc.) and Genespring (Agilent, 
Amstelveen, The Netherlands) and is quantile normalized log2 transformed data is provided in 




CD271 (C40-1457) was obtained from Beckton Dickinson (BD) Biosciences (Breda, The 
Netherlands). Cells were incubated with antibody at 4˚C for 30 min. For blocking nonspecific binding 
to Fc receptors, cells were blocked with mouse and human anti-Fc antibodies for 10 min at 4˚C. All 
FACS analyses were performed on a FACS Calibur (Becton Dickinson) and data was analyzed using 
Flow Jo (Tree Star, Inc.). Cells were sorted on a Mo Flo (Beckman Coulter). 
 
Extraction of polar metabolites and NMR spectroscopy 
 
CB or CB transduced BCR-ABL day 20 cells (+/- 24 hours of hypoxia) were used for NMR analyses. 
20-30 million cells were quenched and the intracellular metabolites were extracted, evaporated using 
a SpeedVac concentrator and stored at -80˚C until further analysis. For the NMR analysis dried 
samples were resuspended in 60 µl of 100mM sodium phosphate buffer containing 500 mM TMSP 
((3-trimethylsilyl) propionic-(2,2,3,3-d4)-acid sodium salt) and 10% D2O, pH 7.0. Samples were 
vortexed, sonicated and centrifuged briefly, before being transferred into a 1.7mm NMR tube using 
an automated Gilson sample handler. One-dimensional 1D 1H-NMR spectra were acquired using a 
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600-MHz Bruker Avance III spectrometer (Bruker Biospin) with a TCI 1.7mm z-PFG cryogenic 
probe at 300 K. Each sample was automatically tuned, matched and then shimmed before acquisition 
of the spectrum. Spectra were processed using the MATLAB-based MetaboLab software [39]. The 
chemical shift was calibrated by referencing the TMSP signal to 0 ppm. Spectra were exported into 
Bruker format for metabolite identification and to determine concentrations using the Chenomx 7.0 
software. The extracellular metabolites were measured directly in the used culture medium. All data 




For antigen detection, sample preparation, SDS electrophoresis and transfer was performed as 
described before [31]. The PVDF-FL membrane (Millipore, EttenLeur, The Netherlands) was 
blocked in odyssey blocking buffer (Westburg, Leusden, The Netherlands) and further probed with 
SLC1A5 (D7C12, Cell Signaling, Bioké, Leiden, The Netherlands) and  -actin (sc-47778, Santa 
Cruz Biotechnology, CA) as loading control primary antibody and further detected with Alexa680 
and IRDye800 fluorescent conjugated secondary antibodies (Invitrogen, Breda, the Netherlands). The 
membrane was visualized using odyssey infrared scanner (Li-Cor Biosciences, Lincoln, NE, USA). 
Signal intensities were quantified using Image studio Lite software (Li-Cor Biosciences, Lincoln, 




K562 cells were maintained in IMDM growth medium with 10% FCS and 1% Penicillin and 
streptomycin and day 20 cells were used for extracellular flux analyses by seahorse. About 0.1-0.15 
million cells were seeded per well in poly-L-lysine (Sigma-Aldrich) coated XF-24 well cell-culture 
microplates in XF Assay media supplemented with 0.1g/L of glucose (Sigma-Aldrich) and 0.5mM 
of sodium pyruvate (Gibco). The cellular oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) were obtained using an XF24-3 analyzer and XF24 FluxPak from Seahorse 
Bioscience. The measurement of OCR was performed using XF cell Mito stress kit according to 
manufacturer’s instructions. Data was analyzed using Wave (Seahorse bioscience) software.  
 
Statistical analyses  
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All statistical analyses was performed using the student t test (unpaired, two-tailed) and were 
expressed as means ± SEM for all other comparisons. Differences were considered statistically 




BCR-ABL imposes hypoxia-like transcriptome changes in human CD34+ cells under normoxic 
conditions. 
 
In order to study mechanisms by which oncogenes impact on the metabolism of leukemic cells we 
transduced human CB CD34+ cells with BCR-ABL and performed a genome wide transcriptome 
analysis. Data were compared to transcriptomes of various other human leukemia models we had 
generated over the years, including CB CD34+ cells transduced with MLL-AF9 [32], FLT3-ITD [40], 
NUP98-HOXA9 [34], STAT5A [13,30,36,41] and KRASG12V [38] (Figure1A, Supplementary Table 
S1). Gene Set Enrichment Analysis (GSEA) was performed on BCR-ABL-transduced CB CD34+ 
cells which revealed, as expected, a strong enrichment for STAT5 and MYC signatures. Interestingly, 
we also found strong enrichment for hypoxia, response to stress and glucose metabolism gene 
signatures (Figure 1B). Since we observed an enrichment for hypoxia signatures, data were also 
compared to transcriptomes of CB CD34+ cells grown under hypoxia, or CB CD34+ cells expressing 
activated HIF1AP402A,P564A HIF2AP405A,P531A [31]. Indeed, a strong enrichment was observed in BCR-
ABL expressing cells for a common hypoxia signature we identified previously [31] (Figure1C, D). 
We then compared NES scores for enrichment of our common hypoxia signature in various oncogene 
models, which showed the highest enrichment in BCR-ABL, KRAS and STAT5 expressing cells, 
poor enrichment in NUP98-HOXA9 expressing cells, and even a negative enrichment in MLL-AF9 
expressing cells (Figure1C). Some GSEA plots are shown in Figure 1D, highlighting that BCR-ABL 
but not MLL-AF9 expressing cells showed enrichment for hypoxia and STAT5 signatures. NUP98-
HOXA9 and MLL-AF9 share a common HOXA-MEIS1-PBX signature that is also seen in 
NPMcytleukemias [42-44]. Indeed, we observed that MLL-AF9 cells, but not BCR-ABL cells, were 
enriched for NPMcyt signatures from primary patient AML samples [44] (Figure1D). Together, these 
data suggest that there is a strong variation in the level at which oncogenes can impose hypoxia-like 
signaling on cells, possibly suggesting a stronger  dependency of BCR-ABL cells on intrinsic hypoxic 
signaling as compared to other oncogene models.  
 
Many glucose metabolism related genes like SLC2A3, SLC2A1, HIF1, HIF2 (Figure 1E) and STAT5 
target genes like CCL2, OSM, PIM1, SOCS1 and SOCS2 (Figure 1F) were upregulated in BCR-ABL 
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cells as determined by IlluminaBeadArrays. Upregulation of SLC2A1, SLC2A3, HIF2, SOCS and 
GYPA was further validated by performing real-time QPCRs on control and BCR-ABL cells 
(Figure1G). In summary, these data suggested that BCR-ABL imposes hypoxic signaling under 




Figure 1. BCR-ABL imposes hypoxia-like transcriptome changes in human CD34+ cells under 
normoxic conditions. A) Various oncogene-models in human CB CD34+ cells have been generated 
and genome-wide transcriptome analyses was performed. B) GSEA of the BCR-ABL transcriptome 
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data using Broad sets GO and ONCOGENIC SIGNATURES. Highest scoring term was ‘response to 
hypoxia’. C) GSEA of transcriptomes of various oncogene models using a common hypoxia signature 
we defined previously in CB CD34+ cells [25]. NES scores are shown. All FDR q-values are 
significant and below 0.25, except for NUP98-HOXA9. D) GSEA plots indicating that BCR-ABL 
but not MLL-AF9 cells are enriched for hypoxia and STAT5 signatures, while MLL-AF9 cells are 
enriched for NPMcyt signatures, as expected. E) Upregulated metabolism genes in BCR-ABL cells 
as determined by Illumina Bead Array. F) Upregulated STAT5 target genes in BCR-ABL cells as 
determined by Illumina Bead Array. G) Validation of Illumina Bead Array data by Q-PCRs. 
 
Knockdown of HIF1 or HIF2 in the absence of bone marrow stroma leads to a proliferative 
disadvantage in BCR-ABL stem/progenitor cells.  
 
The hypoxia-induced transcription factors (HIF1 and HIF2) are normally upregulated and stabilized 
under hypoxic conditions in the bone marrow microenvironment, but we noted upregulation by BCR-
ABL under normoxic conditions as well, in line with what we observed previously for STAT5-
induced HIF2 upregulation [13]. To determine whether HIFs play an important role in the 
transformation potential of BCR-ABL expressing stem/progenitor cells we used a lentiviral shRNA 
approach to down-regulate HIF1 and HIF2 and efficient down-regulation was validated at the RNA 
level (Figure 2a-b). Moreover, HIF1 levels were unaltered in HIF2 down-regulated cells indicating 
specificity of the short hairpins, while HIF2 levels were slightly increased in HIF1 down-regulated 
cells suggesting compensatory mechanisms (Figure 2b). Next, cells were expanded in liquid culture 
conditions driven by SCF, TPO and FLT3L over a period of 30-50 days, and a reduced output was 
noted upon either loss of HIF1 or HIF2 (Figure 2c). Morphological analyses by MGG staining 
indicated a more differentiated phenotype at day 44 upon HIF1 and HIF2 down-regulation, while 
BCR-ABL cells treated with SCR hairpin appeared more immature and blast-like (Figure 2d), in line 
with what was observed previously [45]. The clonogenic potential of BCR-ABL+ cells was also 
slightly reduced upon HIF1 and HIF2 down-regulation when analyzed by colony forming cell (CFC) 
assays in methylcellulose (Figure 2e). Together, these data indicate that down-regulation of HIF1 or 
HIF2 results in considerable impairment in proliferation of BCR-ABL stem/progenitor cells, and also 
that HIF transcription factors fulfill, at least in part, non-redundant functions in BCR-ABL 
stem/progenitor cells. Over the time-course of these experiments apoptosis was measured frequently 
by AnnexinV FACS analyses, but no signs of enhanced apoptosis upon knockdown of HIF1 or HIF2 
were observed (data not shown). We also evaluated the role of HIF1 and HIF2 in BCR-ABL 
expressing cells when grown on a protective bone marrow stromal microenvironment. Intriguingly, 
HIF1 and HIF2 down regulation had negligible effects on cell the proliferation or colony output when 
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BCR-ABL stem/progenitor cells were cultured on MS5 stroma (data not shown), suggesting that the 





Figure 2. Functional relevance of HIF1 and HIF2 in BCR-ABL stem/progenitor cells grown 
under liquid culture conditions. a-b) Down-regulation of HIF1 and HIF2 by respective short 
hairpins in BCR-ABL positive cells as compared to scrambled controlwas validated by q-PCR. c) 
Knockdown of HIF1 or HIF2 impaired growth of BCR-ABL positive cells under liquid culture 
conditions. Data shown is representative of n=3. d) MGG stainings at day 44 (63X magnification). 
e) Methylcellulose assay indicated reduced colony forming ability of BCR-ABL positive cells upon 
down-regulation of HIF1 and HIF2 at day 10, p-value<0.05 as indicated in panel. 
 
Hypoxia-induced metabolic changes in BCR-ABL stem/progenitor cells. 
 
Next we studied metabolic changes in BCR-ABL+ cells cultured under normoxia or hypoxia using 
1D 1H NMR spectroscopy. We observed striking differences in various metabolites when CB CD34+ 
cells transduced with BCR-ABL were compared to normal control cells grown under normoxia or 
hypoxia. As expected, BCR-ABL cells exhibited enhanced glycolysis as determined by an increased 
production of lactate under normoxic conditions which was further increased under hypoxic 
conditions in comparison to control cells (Figure 3A). Lactate production was also slightly increased 
in control cells when grown under hypoxia (Figure 3A). Apart from lactate and pyruvate, certain 
amino acids like glutamine, methionine, valine, isoleucine, phenylalanine, tryptophan, tyrosine and 
also metabolites related to cellular senescence were increased in BCR-ABL as compared to CB cells 
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under normoxia and hypoxia (Figure 3A). No significant changes were seen in TCA cycle metabolites 
(Figure 3A).  
 
To confirm these initial data additional independent experiments were performed focusing on 
glycolysis and glutaminolysis (Figure 3B). Again, increased levels of lactate were observed in BCR-
ABL cells compared to control cells under normoxic conditions, which was further enhanced under 
hypoxia (Figure 3B). We also measured the secretion of lactate, which was increased by BCR-ABL 
under normoxia as well as under hypoxia (Figure 3B). Furthermore, intracellular glutamine and 
arginine were increased in BCR-ABL cells, however no particular difference was observed in 
intracellular glutamate levels in BCR-ABL cells compared to CB cells (Figure 3B). These data 
suggest that the increase of glutamine in cells reflects rapid glutamine uptake, with a steady-state 
intermediate concentration of glutamate which is immediately used up by the Krebs cycle, explaining 
why glutamate levels themselves are not altered. Although the observed differences did not reach 
statistical significance, probably due to some variation in the absolute concentrations of metabolites 
that were measured in the individual NMR analyses, the trends were always consistent across multiple 
independent experiments. Finally, metabolome analyses were repeated in BCR-ABL cells upon 
knockdown of HIF1 or HIF2. Most notable changes included a decrease in lactate, o-phosphoserine 




Figure 3. Effect of hypoxia on metabolic changes in BCR-ABL versus normal CB cells as 
measured by NMR. A) Metabolites were quantified using 1D 1H-NMR in CB CD34+ control cells 
and transduced CB BCR-ABL cells, cultured under normoxia or placed at hypoxia 24 hrs prior to 
lyses. Lactate levels were increased in control CB cells grown under hypoxia, and enhanced levels of 
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lactate, pyruvate and glutamate were observed in BCR-ABL+ cells even under normoxic conditions. 
In order to further study glutaminolysis (schematically depicted in B) additional experiments were 
performed to determine intracellular and extracellular levels of several metabolites. Average levels 
of 2 independent experiments are shown. C) 1D 1H-NMR analysis showed reduced intracellular 
levels of lactate and glutamine in BCR-ABL cells upon down-regulation of HIF1 or HIF2. 
 
BCR-ABL cells are dependent on glutamine as an extra source of carbon. 
 
The enhanced glutaminolysis observed in BCR-ABL-expressing cells prompted us to study this in 
more detail. First, the expression of the high affinity importer of glutamine, SLC1A5 (ASCT2) was 
determined in BCR-ABL cells as compared to normal cells. SLC1A5 was higher expressed in BCR-
ABL cells as compared to controls (Figure 4A). These data suggested that enhanced glutamine uptake 
might be used by BCR-ABL positive cells to convert glutamine to glutamate by glutaminase and 
finally into alpha-ketoglutarate to maintain TCA cell cycle activity in glycolytic cells (Figure 4B). 
We hypothesized that targeting this pathway by BPTES (a glutaminase inhibitor) might provide 
alternative means to target BCR-ABL positive cells. BCR-ABL expressing stem/progenitor cells 
were expanded for a period of 3 weeks in the presence of 20µM and 40µM BPTES. A dose-dependent 
inhibition of cell proliferation was evident in BCR-ABL positive cells (Figure 4C).  Control cells 
were also treated with BPTES. Only a negligible non-significant effect of BPTES was observed at 
20µM, while at higher doses of 40µM a mild but significant reduction in proliferation was seen in 
normal cells as well (Figure 4D). Furthermore, the clonogenic potential ability of BCR-ABL positive 
stem/progenitor cells was also compromised in a dose dependent manner upon treatment with BPTES 
(Figure 4E). Although normal progenitor cells were also decreased upon BPTES treatment these data 





Figure 4. Inihibition of Glutaminase impairs proliferation of BCR-ABL+ CB cells. A) Enhanced 
expression of SLC1A5 in K562 and CB BCR-ABL cells as compared to empty vector transduced 
MiNR1 CB cells. B) Schematic representation of glutaminolysis to participate as an extra anaplerotic 
carbon. C) Normal CB cells showed no significant effect with 20 µM of BPTES however higher dose 
of 40 µM semmed to be toxic. D) Dose dependent impaired proliferation observed selectively in 
BCR-ABL cells as compared to normal CB cells at 20 µM and 40 µM BPTES. E) Cologenic 
capability of BCR-ABL cells was compromised in presence of BPTES, p value: BCR-ABL untreated 
vs BCR-ABL 20 µM =0.0032; BCR-ABL untreated vs BCR-ABL 40 µM = 0.0117. F) OCR 
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measurements in K562 cells treated with BPTES using Seahorse. G) OCR measurements in CB 
CD34+ cells transduced with BCR-ABL and treated with BPTES using Seahorse. H) Two primary 
leukemia CD34+ patient samples (#1 in open bars, BC-CML sample; and #2 in striped bars, IDH1 
mutant AML) were grown on MS5 stroma in the absence or presence of BPTES and cumulative 
expansion is shown, p values:  #1 0µM vs #1 20µM = 0.0085; and #2 0µM vs #2 20µM = 0.0017. I) 
Six CD34+-sorted chronic-phase (CP) CML samples were grown on MS5 stroma in the absence or 
presence of BPTES.p-values: *<0.05, **<0.01, n.s.=not significant. 
 
Treatment with BPTES alters the oxygen consumption rate in BCR-ABL expressing cells. 
 
In order to functionally understand the bioenergetic dependency of K562 on glutamine, the 
mitochondrial respiration rate and glycolysis rate were determined for K562 treated with 20µM and 
40µM of glutaminase inhibitor BPTES and compared with rates for untreated K562 over time. The 
specific changes in oxidative phosphorylation (OXPHOS) as indicated by oxygen consumption rates 
(OCR) and in glycolysis as indicated by extracellular acidification rate (ECAR) were detected in real-
time using the seahorse extracellular flux technology. In line with experiments using CB CD34+ cells 
transduced with BCR-ABL, K562 cells also showed reduced proliferation and dose dependent 
sensitivity to 20µM and 40µM of BPTES (data not shown). Treatment with BPTES had an 
insignificant effect on ECAR levels in K562 cells indicating no difference in glycolytic rates on 
BPTES treatment but the observed OCR however was significantly altered even with 20µM or 40µM 
of BPTES (Figure 4F). Similar results were obtained with CB CD34+ cells transduced with BCR-
ABL upon treatment with BPTES (Figure 4G). These results indicate that OXPHOS is compromised 
upon BPTES treatment in BCR-ABL expressing cells. Furthermore, glutamine has been suggested to 
be an important anaplerotic factor for AML with mutations in IDH1/2 [46]. We compared the 
sensitivity for BPTES treatment of a BC-CML patient sample (#1, open bars) with an IDH1 mutated 
AML (#2, striped bars). As expected, BPTES significantly suppressed the growth of primary IDH1 
mutant AML cells as well as BC-CML cells, suggesting a clear glutamine dependency in both cases 
(Figure 4H). Furthermore, 6 CP-CML patient samples were analyzed, and 5/6 displayed a significant 




An enhanced Warburg effect is a prominent feature of many cancers, yet the molecular mechanisms 
are poorly understood. Alternatively, glutaminolysis enables cancer cells to undergo oxidative 
metabolism through the TCA cycle. However, a complete understanding of the metabolic alterations 
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due to transcriptional dysregulation via specific oncogenes and tumor suppressors is currently 
lacking.  
 
Different oncogenes induce different transcriptome changes and thus rely on diverse molecular 
pathways and signaling networks for propagating leukemia. From this study, we indeed observe that 
expression of BCR-ABL drives cells into glycolysis, coinciding with an upregulation of various 
glycolytic enzymes such as glucose importers and hexokinases. Intracellular levels of pyruvate and 
lactate were increased, and also outside the cells an increase in secreted lactate was detected, even 
under normoxic conditions. Furthermore, it is evident that BCR-ABL-mediated cell-intrinsic changes 
induce expression of HIF1 and HIF2 transcription factors under normoxia. We find that BCR-ABL 
stem/progenitor cells are dependent on HIF signaling in well oxygenated conditions in particular in 
the absence of a protective bone marrow niche. However, in the presence of bone marrow stromal 
cells this effect is insignificant, suggesting that the niche might compensate for the loss of HIF1 and 
HIF2. Furthermore, it appears that MLL-AF9 does not utilize hypoxia-like signaling as much as BCR-
ABL-expressing cells do, at least under normoxic conditions. Like MLL-AF9 cells, NUP-98-HOXA9 
and NPMc+ leukemic cells are characterized by high expression/activation of the HOXA9-MEIS1-
PBX axis and cells expressing these oncogenes displayed less overlap with hypoxia/HIF signatures 
compared to BCR-ABL cells. It is possible that HIF1/2 expression is directly upregulated by BCR-
ABL-specific pathways, and indeed especially HIF2 can be directly induced by STAT5 thereby 
enhancing glycolysis as we described previously [13]. STAT5 is also hyperactivated in FLT3-ITD+ 
AMLs, and CB CD34+ cells transduced with FLT3-ITDs  also displayed relatively strong overlap 
with hypoxia signatures. However, most likely alternative pathways apart from STAT5 must play a 
role as well since HIF1 is upregulated in BCR-ABL expressing cells, but is not induced by STAT5 
[13]. STAT5 is not known to be strongly activated by RASG12V, while a significant enrichment with 
hypoxia signaling was seen in those cells as well, and maybe it is particularly MYC that drives 
hypoxia-like signaling in these cells. Finally, since both the loss of HIF1 or HIF2 impaired 
proliferation of BCR-ABL positive cells these data suggest that non-redundant functions of HIF 
transcription factors might exist, but this is currently unclear and further future studies are required 
to obtain insight into these differences. 
 
Our studies show that BCR-ABL positive cells also undergo glutaminolysis despite of pronounced 
glycolysis, suggesting a key role of glutamine as an extra source of carbon in replenishing TCA 
metabolites. This was evident from increased intracellular glutamine levels in BCR-ABL cells under 
normoxia as well as under hypoxia. In line with these observations, the glutamine importer SLC1A5 
was also overexpressed in BCR-ABL-expressing cells, both at the RNA as well as protein level.  
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It has been shown that erythroid differentiation also requires glutamine-dependent de novo nucleotide 
biosynthesis [47]. Others and we have shown that erythroid differentiation is also induced upon 
retroviral transduction of BCR-ABL [28,48,49], activated STAT5 [35,37,50], or FLT3-ITD [33] in 
CB CD34+ cells, leaving open the possibility that the enhanced glutaminolysis would be, In part, also 
related to erythroid differentiation. Future studies are required to resolve these issues, but we have 
also analyzed glutamine dependency in a panel of BCR-ABL+ CP-CML and BC-CML patient 
samples, as well as in an IDH1 R132H-mutant AML sample where this erythroid skewing was not 
observed. In 5/6 CP-CML samples as well as in the BC-CML sample a significant reduction in 
proliferation was observed. Interestingly, in IDH1-mutant AML, sensitivity to BPTES was also noted, 
in line with previously published data [24]. 
 
Since we observed that the intracellular glutamine levels were reduced upon HIF down regulation it 
may suggest that SLC1A5 expression might be under control of these transcription factors, but we 
have not been able to observe changes in expression of SLC1A5 in HIF1/2-knockdown cells. 
Possibly, it is the activity of the glutamine importer that might be affected by HIFs, although 
mechanisms are currently unclear. What is very clear is that conversion of glutamine to glutamate is 
critically important for BCR-ABL cells since treatment with BPTES strongly impaired growth to a 
much higher extent compared to normal CB CD34+ cells, identifying glutamine as a crucial 
anaplerotic precursor. The canonical glutaminolysis pathway generates less ATP by converting 
glutamine to lactate. However, glutamine when oxidized by the TCA cycle can yield 3.5 times more 
energy as compared to the canonical pathway [25]. Our study indicates no change in lactate levels 
when treated with 20µM or 40µM BPTES at ECAR levels but OCR levels were significantly affected 
suggesting efficient use of glutamine for effective oxidation. It is thus interesting to note that intact 
TCA cycling does take place even in the presence of HIFs at normoxia in BCR-ABL stem/progenitor 
cells. Earlier studies have shown a metabolic shift towards enhanced glycolysis by shunting pyruvate 
for TCA by inhibition of PDH, essential to maintain HSCs in a quiescent state under hypoxia [14]. It 
might very well be the case that in BCR-ABL stem/progenitor cells grown under normoxia, the cell 
cycle is kept under control via similar mechanisms, possibly also involving HIFs, in order to prevent 
for instance the detrimental effects of a high ROS buildup in the mitochondria and/or oncogene-
induced senescence. On the other hand, BCR-ABL cells appear to become even more dependent on 
glutamine to maintain TCA cycling.  
 
Besides HIFs, we also observe a strong upregulation of MYC by BCR-ABL and it appears likely that 
alternative pathways driven by cMYC will also be relevant to meet the biosynthetic demands of BCR-
ABL stem/progenitor cells. Along with IDH1/2 mutated AML it is intriguing that BC-CML primary 
 111 
cells are also sensitive to BPTES thus exhibiting glutamine dependency even in the presence of 
glucose (Figure 4H). It will be very interesting in future studies to evaluate whether this addiction 
can be exploited clinically to treat CML cells with BPTES along with tyrosine kinase inhibitors 
(TKIs). In conclusion, our combined transcriptome as well as metabolic profiling approach 
demonstrated that BCR-ABL cells adopt a glucose-dependent glycolysis as well as a glutamine-
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Stem cell self-renewal, survival and differentiation are regulated by an intricate interplay between 
intrinsic and extrinsic factors. While these intrinsic and extrinsic factors are not always necessarily 
separate entities and crosstalk between these entities does exist, intrinsic factors include for instance 
epigenetic regulators and alterations in metabolic pathways induced by the expression of oncogenes, 
while extrinsic factors include cues that HSCs receive from their supportive bone marrow niche 
[1][2]. Thus, intrinsic as well as extrinsic signals, either alone or in coordination, control stem cell 
fate and survival of both normal as well as leukemic stem cells. With these features in mind, we set 
out to develop models that would faithfully recapitulate BCR-ABL-induced leukemia in order to 
further unravel the molecular mechanisms involved in leukemic transformation.  
 
The t(9;22) chromosomal translocation results in expression of the BCR-ABL oncogene, which 
rewires a signaling network that controls a plethora of diverse cellular functions including 
proliferation, differentiation, adhesion, and metabolism,  all potentially contributing to malignancy. 
CML was the first known malignancy to be associated with a characteristic chromosomal aberration 
and many downstream signaling pathways have since been deciphered, yet various aspects of the 
molecular pathology of disease initiation and progression remain obscure. One of the approaches has 
centered around the development of suitable mouse models to mimic leukemia development in vivo. 
With the continuous improvement of immuno-compromised mouse models, much knowledge has 
been acquired. From severe combined immunodeficient (SCID) mice which lack functional B and T 
cells till Non-Obese Diabetic (NOD)-SCID mice which are IL2 receptor gamma chain deficient (NSG 
mice) without functional B, T, and NK cells, significant progress has been made to study the 
engraftment kinetics and propagation of leukemia for CML as well as for AML. In order to further 
understand mechanisms underlying CML, various labs have generated mouse models using different 
technical approaches with the aim to identify molecular mechanisms, collaborating hits, leukemic 
potential and subtype of leukemia developed by 3 different BCR-ABL isoforms. These mouse models 
were also used to study leukemic stem cell properties and alternative treatment options. As reviewed 
in Chapter 2 significant progress has been made in the molecular understanding of CML with the 
establishment of different mouse models. Future challenges and opportunities lie in the development 
of induced pluripotent cell lines (iPS) for CML as outlined in chapter 2. From the identification of 
specific of specific subclones to the development of kinase-specific targeted therapies, a major focus 
is now also on kinase-independent pathways and to understand how a ‘leukemia-specific' niche can 
foster the growth of leukemic stem cells (LSCs) in CML. Recent studies indicate a protective role of 
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the niche to evade chemotherapy, and a thorough  understanding of these features be used in feature 
therapeutic strategies to target CML LSCs [3].  
 
As we have shown previsouly, co-expression of BCR-ABL together with the polycomb repression 
complex 1 (PRC1) member BMI1 in human cord blood (CB) derived CD34+ cells is sufficient to 
induce a serially transplantable lymphoid leukemia [4]. Although in vivo no myeloid leukemia was 
observed, in vitro both lymphoid as well as myeloid immortalized long-term cultures could readily 
be established, in line with phenotypes observed in chronic myeloid leukemia patients whereby a 
chronic myeloid phase can egress into a myeloid or lymphoid blast crisis. It is very plausible that 
differences between murine and human hematopoietic stem cell niches underlie these observed 
differences. Since NSG models are typically lymphoid-biased due to the absence of species-specific 
myeloid growth factors, we hypothesized that extrinsic factors might dictate lineage fate. Using a 
“humanized” NSG mouse model in which scaffolds seeded with human mesenchymal stem cells were 
implanted we observed that, in contrast to the murine niche, BCR-ABL overexpression alone was 
sufficient to induce a serially transplantable leukemia B-ALL and primary AML could be induced 
(chapter 3). Efficient engraftment of a blast-crisis CML patient sample was also observed whereby 
the immature blast-like phenotype was maintained in the human scaffold niche, but to a much lesser 
extent in murine niches. In vitro, long-term self-renewing cultures could readily be established with 
cells retrieved from the human scaffold niche of these leukemic mice while no long-term cultures 
could be initiated with cells retrieved from the murine bone marrow niche. Genome-wide 
transcriptome analyzes of leukemic cells retrieved from the mouse BM niche and from the human 
scaffold niche revealed striking differences in gene expression imposed on BCR-ABL+ cells by these 
different environments. For example, endogenous BMI1 levels were significantly higher in BCR-
ABL cells retrieved from human scaffold niche as compared to murine BM harvested cells suggesting 
that BMI1 might still be required as an additional factor to prevent oncogene-induced senescence. 
 
Apart from epigenetic modifiers, we hypothesized that the hypoxic microenvironment might play an 
important role in maintaining CML LSCs as well and studied that in detail (chapter 4). Hypoxia 
inducible factor 1α (HIF1) and HIF2 act as transcription factors that are stabilized under hypoxic 
conditions. HIF1 has been characterized as an important factor that controls cellular metabolism while 
the role of HIF2 is still less clear. Earlier we identified HIF2 as a downstream target of STAT5 and 
observed elevated glucose uptake in HSCs expressing activated STAT5. Several genes associated 
with glucose metabolism were upregulated by STAT5 in an HIF2-dependent manner, including 
SLC2A1 and GYS2. Here, we investigated metabolic changes in BCR-ABL expressing human 
stem/progenitor cells and focused on the role on HIF1 and HIF2. Genome-wide transcriptome 
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analyzes were performed on human CB CD34+ cells transduced with BCR-ABL as well as on BCR-
ABL-positive CML and B-ALL patient samples. GSEA analyzes indicated that these transcriptome 
changes were strongly enriched for STAT5 and MYC signatures as well as for hypoxia, embryonic 
stem cell and glucose metabolism gene signatures which included upregulation of e.g. SLC2A3, 
SLC2A1 and HIF1 and HIF2. These data suggest that BCR-ABL imposes hypoxic signaling under 
normoxic conditions. Moreover, downregulation of HIF1 and HIF2 using a shRNA approach 
impaired proliferation and reduced progenitor frequencies of BCR-ABL+ cells. Next, we studied 
metabolic changes in BCR-ABL+ cells using NMR. We observed striking differences in uptake and 
secretion of metabolites when BCR-ABL CB CD34+ cells were compared to normal CB CD34+ cells 
under normoxia and hypoxia. As expected, BCR-ABL cells exhibited enhanced glycolysis as 
determined by an increased production and secretion of lactate under both normoxic and hypoxic 
conditions. Interestingly, glutamine levels were strongly enhanced in BCR-ABL+ cells, in a HIF1/2-
dependent manner, possibly via enhanced glutamine import or glutamine production via 
upregulation/activation of Glutamine Synthase (GS) which is typically seen when cells undergo 
autophagy. We first analyzed the expression of glutamine importer SLC1A5 in K562 and CB CD34+ 
transduced BCR-ABL and normal cells. As expected, levels of SLC1A5 were increased in BCR-ABL 
cells as compared to K562 and normal CB cells at protein levels. In order to the understand role of 
glutamine in CML, we blocked glutaminase with BPTES and analyzed its effect at 20 and 40 µM on 
normal and CB-transduced BCR-ABL cells. BPTES treatment with 40 µM dose was toxic for normal 
CB cells however no significant effect was seen at a dose of 20 µM on normal cells. BCR-ABL cells, 
however, showed significantly impaired proliferation at both 20 and 40 µM. Furthermore, treatment 
of K562 cells with 20 µM BPTES resulted in a decreased oxygen consumption rate. Treatment with 
BPTES was also effective on primary AML patient samples with an IDH1 mutation or BCR-ABL 
translocation, as well as on 5/6 tested chronic phase CP-CML patient samples. Expression of the 
glutamine importer SLC1A5 was elevated in BCR-ABL+ cells, and together with an increased 
susceptibility of BCR-ABL stem/progenitor cells to BPTES and a decreased OCR upon BPTES 
treatment indicated that glutamine was used as an alternate carbon source to maintain TCA cell cycle 
activity in glycolytic cells. Our data also suggested a link between cell intrinsic regulation of HIF1 
and HIF2 and glutamine uptake in BCR-ABL+ cells, but in future studies, it will be of interest to 
verify whether the hypoxic microenvironment or intrinsic HIF regulation indeed have direct links 
with the control over glutamine metabolism. Further studies using appropriate in vivo models that 
focus on targeting this pathway would be useful to decipher the role of intrinsic HIF regulation in 






In our previous studies we have always observed that only cells that expressed BCR-ABL together 
with the polycomb group protein BMI1 displayed a proliferative advantage and could give rise to 
serially transplantable CD19+ B-ALL in NOD-SCID as well as NSG mouse models without a human 
niche. Also in vitro, co-expression of BMI1 was necessary to allow long-term expansion of BCR-
ABL+ cells, and expression of BCR-ABL alone could only give rise to short-term expansion in vitro 
and was not sufficient to induced leukemia in vivo in xenograft models, in line with data published 
by others [5]. Although the mechanisms by which BMI1 contributes to BCR-ABL-induced 
transformation remain to be elucidated, one possibility could be that expression of BCR-ABL alone 
would drive cells into oncogene-induced senescence, a phenomenon that is more often observed [6]. 
Since BMI1 has been shown to repress the INK4A/ARF locus [7], thereby allowing a bypass of 
senescence [4, 8] it is certainly plausible that co-expression of BMI1 is essential to bypass oncogene-
induced senescence by BCR-ABL as well. 
 
In the current humanized bone marrow niche scaffold (hBM-sc) xenograft model, transformation was 
achieved with cells that expressed both BCR-ABL and BMI1, but also with transduced cells that only 
expressed BCR-ABL, indicating that exogenous BMI1 was not an absolute necessity when BCR-
ABL cells were grown in the presence of a human niche. We also performed in vitro experiments 
whereby CB CD34+ cells transduced with only BCR-ABL were grown on murine bone marrow 
stromal cells (MS5) or human mesenchymal stromal cells (MSC) in the absence and presence of 
growth factors, and these data indicated that exhaustion was observed much earlier in the presence of 
murine stroma compared to human stroma (supplementary figure 6a, b in chapter 3). Interestingly, 
the level of expansion was less strong on human stroma compared to murine stroma, again indicative 
that BCR-ABL+ cells run into oncogene-induced senescence much quicker, although molecular 
mechanisms such as expression of the INK4A/ARF locus still need to be evaluated. 
 
As described in chapter 3, one interesting observation was that endogenous BMI1 was up-regulated 
in human scaffold-derived BCR-ABL+ cells as well as in patient-derived primary BC-CML cells 
engrafted in and harvested from human scaffolds. Expression of BMI1 can be controlled by the 
transcription factor GLI1 [9] and Hedgehog signaling is required for maintenance of BCR-ABL stem 
cells [10, 11]. We, therefore, hypothesized that the sonic hedgehog pathway might be involved in the 
upregulation of endogenous BMI1 in BCR-ABL-expressing cells, thereby allowing the propagation 
of a serially transplantable leukemia. Long-term stromal cocultures were performed in the absence or 
presence of exogenous SHH ligand, and we observed that BCR-ABL cells could actively develop 
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blast-like cobblestone forming cells (CAFC) until day 90 of MS5 stromal co-cultures in presence of 
IL3, TPO and SCF cytokines and SHH (figure 1). In contrast, in the absence of SHH ligand, BCR-
ABL single cells could hardly survive for 56 days on MS5 stromal co-cultures. Although the fact that 
day 90 CAFCs could be generated suggesting that a delay in senescence had occurred, these CAFCs 
could not be further replated after day 90, indicating that these BCR-ABL single cells in the presence 
of SHH ligand were not capable of undergoing a full-blown transformation event when cultured on 
murine MS5. These results are in line with what we observed for primary CD34+ CML patient cells 
that could efficiently engraft in our hBM-sc xenograft model, whereby stemness was much better 
preserved in the human environment i.e. in humanized MSC scaffold niche as compared to the mouse 
BM environment. Also in these primary CML cells, BMI1 expression was better maintained when 
cells were grown in the human hBM-sc niche. 
 
Figure 1: The presence of SHH allowed CAFC formation of  BCR-ABL transduced CB cells untill 
day 90 in MS5 stromal cocultures supplemented with IL3,TPO and SCF cytokines. Left panel 
displays a representative image of co-cultures without SHH whereby hardly any cells survived untill 
day 90, right panel displays a representative image of co-cultures with SHH showing CAFC 
formation. 
 
Although further studies are required, together these data might suggest that oncogene-induced 
senescence is not as quickly induced in a human microenvironment compared to a murine 
environment. Besides an upregulation of BMI1, this might also be in part mediated by the high levels 
of BMPs and TGFs that are secreted by the human MSCs under the in vitro growth culture conditions. 
These features might favor a better long-term maintenance and preservation of the original leukemic 
phenotype, and might also suggest that human MSCs better protect CML LSCs to allow increased 
survival. Interestingly, genes associated with hypoxic signaling, MYC, mitochondria and metabolism 
were also observed to be enriched in hBM-sc derived BCR-ABL cells as compared to murine BM 
Without  SHH Plus  SHH   
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BCR-ABL/BMI1 cells, suggesting a possible role for niche-imposing intrinsic transcriptome changes 
that would further contribute to stem cell maintanance.   
 
Various cell intrinsic mechanisms downstream of BCR-ABL like JAK/STAT, PI3K/Akt and others 
are known to impact on the survival and maintenance of CML stem/progenitor cells. However, 
regulation of metabolic process in CML, and certainly in CML LSCs, is poorly understood. Such 
signal transduction pathways to some extent are linked to the regulation of various metabolic 
processes since targeting these pathways also affect metabolism. It is therefore of great interest to 
understand how CML stem/progenitor cells comply to their changing metabolic needs under hypoxic 
and normoxic conditions for survival. Hence, we studied these features in a number of different 
leukemia backgrounds by analyzing the transcriptomes of human CB CD34+ cells transduced with 
oncogenes such as BCR-ABL, MLL-AF9, FLT3-ITDs, NUP98-HOXA9, STAT5A and KRASG12V 
in detail (chapter 4). Our data suggests that BCR-ABL, KRASG12V and STAT5 could impose hypoxic 
signaling under normoxic conditions while other oncogenes seemed less likely to be dependent on 
hypoxic signaling. An up-regulation of glucose importers SLC2A1/3, hexokinases and HIF 1 and 2 
in BCR-ABL cells was observed. These observations, combined with extensive NMR-based 
metabolic profiling in CB CD34+ cells transduced with BCR-ABL versus controls, both cultured 
under normoxia and hypoxia, indicated an increased Warburg effect and glycolysis as revealed by a 
strong increase in lactate and pyruvate levels in these cells, even under normoxia conditions. This 
coincided with enhanced glutaminolysis. Interestingly, NMR studies using CB CD34+ cells 
transduced with BCR-ABL as well as with shRNA vectors to knockdown HIF1 or HIF2 indicated 
that HIF transcription factors were also important for the increase in glutamine levels.  In principle, 
the increase in intracellular glutamine levels might be caused by in expression of the glutamine 
importer SLC1A5, although constitutive expression of normoxia-insensitive HIF mutants did not 
show a direct correlation with increased SLC1A5 receptor (data not shown, Chapter 4). Alternatively, 
other indirect mechanisms might be involved in the enhanced glutamine uptake in BCR-ABL 
expressing cells. One important player might be the transcription factor MYC. MYC-induced 
glutaminolysis to maintain active TCA cycling in the absence of glucose under both aerobic and 
hypoxic conditions has been reported in P493 Burkitt lymphoma cells [12]. Furthermore, high MYC 
levels have been correlated with poor prognosis in CML [13]. Although increased expression of MYC 
is not correlated with the progression from chronic phase to blast crisis phase CML, one study has 
highlighted upregulation of c-myc in resistant CML cells [14]. Furthermore, BCR-ABL expressing 
cells were found to be enriched for MYC signatures by Gene Set Enrichment Analysis (GSEA) 
analyzes as compared to normal CB CD34+ cells (chapter 4). It will be thus of further interest to study 
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the involvement of MYC in altered HIF-mediated glutamine metabolism in BCR-ABL expressing 
cells.  
 
Regardless of the mechanisms underlying glutaminolysis, we observed an increased susceptibility to 
the glutaminase inhibitor BPTES in BCR-ABL expressing cells (chapter 4). Also, oxygen 
consumption rates decreased in K562 cells treated with BPTES, indicating a glutamine dependency 
for oxidative phosphorylation. Apart from being the anaplerotic precursor, glutamine when oxidized 
by the TCA cycle can yield 3.5 times more energy as compared to canonical glutaminolysis pathway 
[12]. In conclusion, studies presented in this thesis suggest that BCR-ABL-positive cancer cells make 
use of enhanced glutamine metabolism to maintain TCA cell cycle activity in glycolytic cells, and 
that targeting this pathway might have therapeutic benefit.  
 
As depicted in figure 2, collectively our data show that: 
  
•   Establishment of a human niche allows induction of transplantable ALL and increased 
incidence of AML by human CB CD34+ cells expressing BCR-ABL without additional 
exogenous hits 
•   Self renewal of BC-CML LT-LSCs could be better maintained in the presence of a 
humanized scaffold niche.  
•   BCR-ABL can impose hypoxic signaling under normoxic conditions. 
•   BCR-ABL-positive cells are highly dependent on glutaminolysis along with glycolysis and 
















Figure 2: Potential role of extrinsic and intrinsic cues in mediating BCR-ABL leukemogenesis. 
In the presence of murine bone-marrow niche (mBM), BCR-ABL along with BMI1 induces a serially 
transplantable lymphoid leukemia whereby BCR-ABL expression alone is sufficient to induce 
serially transplantable lymphoid as well as myeloid leukemia in the presence of human bone-marrow 
like scaffold niche (huBM-sc). This difference in leukemic phenotype can be probably due to the 
presence of humanized niche providing human growth factors like SCF, IL3, SPP1 to maintain 
myeloid clones as well as extrinsic cues e.g. SHH ligand upregulate endogenous BMI1 which 
prevents oncogene-induced senescence or stem cell exhaustion. Furthermore, internal regulator HIF 
transcription factors maintain a specific metabolic state of BCR-ABL+ stem/progenitor cells by 
enhancing dependency on glutamine along with active glycolysis under normoxia. Our current 
understanding suggests that cell autonomous regulation of glutamine dependency and crosstalk with 
suitable humanized tumor microenvironment provide necessary cues for priming BCR-ABL positive 




Modeling of leukemias and their niche 
 
In order to truly begin to understand mechanisms that regulate self-renewal, differentiation and 
transformation of human hematopoietic stem cells, or to evaluate the efficacy of novel treatment 
modalities, stem cells need to be studied in their own species-specific microenvironment. Over the 
past years, a wide variety of in vivo mouse xenograft models have been generated in order to unravel 
the molecular pathology of human leukemias. However, despite the fact that these immunodeficient 
mice are susceptible to a human graft, the environment is murine specific and not human. By 
implanting ceramic scaffolds coated with human mesenchymal stromal cells (MSCs) into immune 
deficient mice described in this thesis we mimic the human bone marrow niche. Thus, we have for 
the first time established a model that allows efficient serial engraftment and leukemia development 
of human CD34+ cells expressing BCR-ABL. Also, primary AML patient samples could efficiently 
engraft and simultaneously a human leukemia xenograft mouse clinic was developed in our lab in 
which a large cohort of patient samples successfully engrafted covering all important genetic and risk 
subgroups. Moreover, evidence suggests that leukemia associated genetic aberrations in MSCs 
contribute to the pathogenesis of the disease [15]. Such humanized models can thus be also 




Not only does this model allow the study of molecular mechanisms underlying human stem cell self-
renewal and leukemic transformation within a humanized environment, additional options lie in the 
ease of genetic manipulation of a human niche itself to study interactions between leukemic cells and 
stroma. On similar lines, the group of Andreeff M. observed 50% reduction in MOLM13 leukemic 
cell engraftment using MSCs in which HIF1alpha was knocked down in an ectopic matrigel bone 
model [17]. These studies nicely demonstrated that in this model the human extramedullary bone 
marrow can be genetically modified allowing fiunction in vivo studies in mice, thereby showing  that 
targeting HIF1a in MSCs in the niche itself might also be  a new approach to improve therapeutic 
strategies for leukemia. Future studies should be aimed at modulating the ‘‘disease specific’’ 
microenvironment for e.g. by gene-editing using a CRISPR/Cas9 approach or by pharmacological 
intervention using antagonists [18]. This might shed light on understanding survival, progression or 
resistance signaling mechanisms of leukemic (stem) cells, and might unravel alternative approaches 
to eradicate LSCs by efficient targeting of LSC-stroma specific interactions. 
 
Furthermore, this model can now serve as a unique platform to validate and study different niche 
based therapeutic molecules. A recent study presented at ASH 2015 by Zeng Z. et. al. investigated 
stroma-mediated drug resistance mechanisms to different inhibitors by proteomic profiling of 
signaling mediated by the microenvironment [19]. One of their findings suggested that activation of 
the PI3k-AKT-mTOR pathway due to the presence of stroma is a common survival mechanism. The 
availability of suitable in vivo humanized models can further facilitate studies aimed at identifying 
the appropriate drug regimens to eliminate stroma-mediated drug resistant leukemic cells.  
 
It is also evident that the metabolic status of leukemic cells is altered under hypoxic conditions within 
the bone marrow microenvironment  [20, 21]. Some studies have performed serum metabolic 
profiling of chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) patient samples [22, 
23]. Moreover, efforts have also been made to use realtime NMR profiling under changing 
oxygenation levels to understand hypoxic adaptation of CLL cells [24]. However, tumor metabolic 
demands in particular of the leukemic bone marrow microenvironment are so far poorly studied [25]. 
It will be interesting in the future to explore which metabolites from the bone marrow 
microenvironment participate in the progression and survival of leukemia. 
 
Targeting the niche as alternative therapeutic approach 
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Leukemic stem cells have long-term repopulating properties to maintain and propagate leukemia in 
the presence of a supporting bone marrow microenvironment. These supporting niches have been 
instrumental in protecting leukemic stem cells from chemotherapy and might eventually serve as a 
cause to give rise to minimal residual disease and relapse. Many studies have suggested 
chemotherapy-induced changes in the stromal microenvironment which further shelter the primitive 
leukemic cells to evade therapy. Thus, strategies to target this therapy-induced bone marrow 
microenvironment to mitigate leukemia relapse is of utmost importance.  
 
Understanding the events resulting from primary therapy on the niche itself are critical in order to 
unravel the consequences associated with their protective role for leukemic cells, as was nicely 
elucidated by the group of Hong [26]. Their studies identify a therapy-induced dynamically transient 
protective niche generated in order to protect ALL leukemia propagating cells from chemotherapy. 
Such alterations in the microenvironment can be a major obstacle to achieve complete remission and 
hence exploring the interplay between leukemia cells and such early protective niches can lead to 
better therapeutic strategies in the future.  
 
In particularly in chronic myeloid leukemia, it has been proposed that IFN-alpha treatment leads to 
inhibition of fibroblast proliferation, alteration of cytokine production as well as modification of the 
extracellular matrix resulting in increased retention of CML cells in bone marrow [27]. Furthermore, 
studies from the group of Konopleva have demonstrated that imatinib treatment upregulates CXCR4 
in CML cells thus allowing them to migrate to the BM where they revert to a quiescent state and 
hence survive therapy [28]. Thus, apart from obliterating leukemic cells, therapy also leads to 
alterations in microenvironment which in a way serves as a ‘foster home’ to further nurture these 
CML LSCs. A detailed understanding of the processes is warranted to further improve future 
therapies for CML. 
 
This reprogramming of the bone marrow microenvironment in response to therapy making the niche 
more suitable to host CML LSCs as compared to normal hematopoiesis is intriguing. In order to 
understand therapy induced alterations in niches, one must revisit studies highlighting ‘malignancy-
induced microenvironment’. Many studies have focused on understanding the role of CML LSCs in 
modulating stroma. Recently published data by Zhang and her colleagues showed decreased 
expression of CXCL12 by BM stromal cells in CP-CML due to the production of G-CSF [29]. 
Furthermore, upon treatment with imatinib, this effect was reversed and long-term HSC growth was 
restored. This study indicated the cross-talk of LSCs with their supporting microenvironment to 
prevent and outcompete normal HSCs for niche occupancy. Further studies from the group of 
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Passegue showed that BCR-ABL-induced remodeling of BM niches can contribute to CML 
pathogenesis and impair normal hematopoiesis [30]. Furthermore, CD44 and selectins have been 
implicated to play an important role in homing and engraftment of BCR-ABL cells as documented 
by studies of Krause et al. [31, 32].  
 
Lately, increasing evidence also suggests the link between the bone marrow microenvironment and 
AML metabolism. Mussai and colleagues imply that AML blast cells alter the microenvironment 
through enhanced arginine metabolism [33]. Enhanced release of Arginase II resulted in suppression 
of T cell proliferation. Furthermore, it was confirmed that inhibition of the immunosuppressive 
activity of AML blasts could be inhibited by using small molecule inhibitors of arginase and inducible 
nitric oxide synthase (NOS). However, due to safety concerns of these compounds especially NOS 
inhibitors, such studies do pinpoint to alternative strategies to target the AML BM niche by interfering 
with arginine metabolism in a clinical setting [34]. Unpublished data presented at ASH 2013 by the 
group of Tsvee Lapdiot also highlighted the importance of niche-mediated energy sharing between 
LSCs and their microenvironment via transfer of mitochondria from LSCs to stromal cells thereby 
reducing stress and/or ROS levels [35]. Such elegant mechanisms of ROS quenching in leukemic 
cells by mitochondrial transfer to stromal cells further uncovers previously unanticipated interactions 
between LSCs and their niche, and might also open up new avenues for targeting. As described in 
this thesis, the humanized bone-marrow like niche model is ideally suited to study the dependence of 
leukemic stem/progenitor cells on specific microenvironmental linked to maintenance of stemness 
and their specific metabolic state. Ultimately, such studies may contribute to the development of 
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Bloed bestaat uit plasma en meer dan 10 verschillende cel types, welke verschillende functies hebben. 
Bloed wordt beschouwd als één van de meest regeneratieve en plastische weefsels, waar per minuut 
miljoenen “oude” bloedcellen vervangen worden door nieuwe. Alle bloed celtypen worden gevormd 
uit zogenaamde hematopoietische stamcellen (HSCs), welke zich in het beenmerg bevinden 
gedurende het volwassen leven. Dit proces wordt hematopoiese genoemd (bloedcel vorming) [1]. De 
zoektocht naar de bloedvormende stamcellen is begonnen in 1945, toen men zag dat mensen die 
blootgesteld waren aan een dodelijke dosis straling, een verminderde hematopoiese hadden. 
Vergelijkbare stralingsziekten werden gezien bij muizen waarbij röntgenopnames van het hele 
lichaam waren gemaakt, deze muizen stierven twee weken na de blootstelling aan röntgenstraling 
door falen van de bloedcel aanmaak [2]. De eerste bewijzen van het bestaan van HSCs kwamen van 
studies waarbij de bestraalde muizen beenmergcellen van een gezonde muis kregen, wat leidde tot 
herstel van de hematopoiese in de bestraalde muizen [3]. Basaal onderzoek volgde en in het begin 
van de jaren 60 begonnen Till en McCulloch de eigenschappen van de beenmergcellen te 
onderzoeken, hetgeen leidde tot de identificatie van HSCs en hun twee unieke eigenschappen: de 





Leukemie is gedefinieerd als kanker van de bloedcellen. Een defect in de eigenschappen van HSCs 
(zelfvernieuwing en/of differentiatie) kan leiden tot de ontwikkeling van hematologische ziekten. 
Deze hematologische afwijkingen worden verondersteld te ontstaan uit leukemische stamcellen 
(LSCs) [5-7]. LSCs gebruiken de regulatiemachinerie van normale HSCs en pikken bepaalde  
genetische veranderingen op en dragen hierdoor bij aan leukemogenese (ontwikkeling en progressie 
van de hematopoietische aandoening) [8]. Deze genetische veranderingen kunnen voorkomen in 
lymphoïde cellen, wat kan lijden tot acute lymphocytische leukemie (ALL) of chronische 
lymphocytische leukemie, of, wanneer ze voorkomen in myeloïde cellen, kan lijden tot acute 
myeloïde leukemie (AML) of chronische myeloïde leukemie [9]. Acuut betekent hier dat de ziekte 
zich snel ontwikkelt, terwijl chronische leukemie voor een langere tijd kan bestaan. Bloedkanker kan 
zich ook manifesteren als multiple myeloma, de ziekte van Hodgkin of non-Hodgkin lymphoma. 
Een bepaalde genetische verandering, de t(9:22) translocatie, resulteert in de expressie van het BCR-
ABL oncogen, welke een verandering geeft van een signaleringsnetwerk in de cel.  Dit netwerk 
controleert een veelheid van verschillende cellulaire functies, waaronder proliferatie (celgroei), 
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differentiatie, adhesie en metabolisme, welke allemaal een bijdrage kunnen leveren aan de ziekte. 
Inzicht in de genetische veranderingen bij CML heeft het ontstaan van gerichte therapieën in de 
bestrijding van kanker sterk bevorderd [10,11]. In mei 2001 werd het medicijn gleevec (imatinib 
mesylate) goedgekeurd door de Food and Drug Administration, welke specifiek aangrijpt op een het 
BCR-ABL eiwit wat geproduceerd wordt in CML kanker cellen. Hierdoor veranderde CML in de 
meeste gevallen van een fatale ziekte in een behandelbare leukemie. Toch worden de leukemie 
veroorzakende cellen niet erg effectief aangepakt door dit medicijn, waardoor patiënten vaak de rest 
van hun leven deze medicijnen moeten blijven gebruiken. Ook bleek imatinib niet effectief meer bij 
een terugkeer van de leukemie [12,13]. Kort nadat duidelijk werd dat dit het geval was, werden er 
nieuwe medicijnen (tweede en derde generatie medicijnen) ontwikkeld [14]. Het wordt verondersteld 
dat de resistentie van CML cellen ten opzichte van de huidige medicijnen komt doordat additionele 
mutaties in het DNA ontstaan, maar daarnaast ook door de omgeving waarin de cellen zich bevinden 
die de cellen kan beschermen tegen de werking van de medicijnen. Een belangrijke focus van de 
experimenten beschreven in dit proefschrift is dan ook het ontwikkelen van muismodellen waarin de 
humane omgeving nagebootst kan worden. Een andere belangrijke focus is het bestuderen van 
celautonome mechanismen die de metabole status van de leukemische stamcellen kunnen veranderen. 
 
Isolatie en karakterisatie van de HSC/LSC 
 
Hematopoietische stamcellen zijn extreem zeldzaam. Het wordt geschat dat 1 op de 10.000 
beenmergcellen en 1 op de 100.000 bloedcellen stamcellen zijn [15]. Hierdoor is het moeilijk om 
deze cellen te isoleren en/of te karakteriseren. De gouden standaard voor de kwantificatie van HSCs 
is het transplanteren van een celpopulatie in bestraalde muizen om vervolgens te bepalen of de muis 
weer een volledig hertel van de hematopoiese krijgt. Wanneer bij een dergelijk experiment de muis 
weer alle verschillende bloedcel types terug krijgt, zat er in ieder geval een functionele stamcel in het 
transplantaat. Deze aanpak wordt ook gebruikt om de eigenschappen van leukemische stamcellen te 
bepalen. Momenteel is het NSG (NOD/Lt-SCID/IL2Rγnull) xenotransplantatie model het meest 
geschikte model om de ontwikkeling van humane leukemie te bestuderen. Deze muizen zijn immuun 
deficiënt, wat wil zeggen dat ze geen immuun systeem hebben waardoor er geen afstoting van 
lichaamsvreemde cellen zoals bijvoorbeeld humane cellen zal optreden. Het is een lange weg geweest 
dit soort immuun deficiënte muizenmodellen te genereren om humane ziekten in te kunnen 
bestuderen. Een uitgebreid overzicht van de verschillende huidige muismodellen en een beschrijving  




Nabootsing van BCR-ABL leukemie in een muis model gebaseerd op humaan beenmerg 
 
Voorgaande studies lieten zien dat wanneer BCR-ABL samen met BMI1 (een epigenetisch 
regulatoreiwit) tot expressie wordt gebracht in humane HSCs dit voldoende is om lymphoïde 
leukemie te induceren na transplantatie in immuun deficiënte NSG muizen [17]. Het bleek echter 
moeilijker te zijn om myeloïde leukemie na te bootsen, terwijl de BCR-ABL mutatie in patienten wel 
degelijk myeloïde leukemie kan veroorzaken. Omdat NSG modellen over het algemeen neigen naar 
lymphoïde groei, veronderstelden we dat extrinsieke factoren (omgevingsfactoren) die in het 
beenmerg aangemaakt worden wellicht in belangrijke mate de differentiatierichting bepalen (in welke 
celtypen de HSCs zich ontwikkelen). Het is ook bekend dat een aantal van dit soort factoren, en met 
name diegene die HSCs aansturen tot myeloïde differentiatie, “species-specifiek” zijn hetgeen wil 
zeggen dat factoren geproduceerd door de muis hun werking niet kunnen uitoefenen op humane 
cellen, alleen op  muizencellen. Om een humane omgeving na te bootsen hebben we gebruik gemaakt 
van NSG muizen waarbij (met humane mesenchymale stroma cellen bedekte) keramische deeltjes 
(scaffolds genaamd) werden geïmplanteerd onder de huid van de muizen. Deze stromale cellen waren 
in staat om te differentiëren in verschillende celtypen die we in de normale beenmergomgeving ook 
vinden om zo een humane microenviroment na te bootsen. Efficiënte botvorming werd geïnduceerd 
op de scaffolds, en daarnaast werden muizen bloedvaten aangelegd naar deze human scaffolds. 
Humane cellen waarin BCR-ABL tot overexpressie gebracht was werden in de scaffolds geïnjecteerd, 
waarna zowel AML alsook ALL ontwikkelde, in tegenstelling tot in het normale muizenbeenmerg 
waarin alleen ALL ontstond. We hebben het genexpressie patroon van deze leukemiën die groeiden 
in de humane scaffold omgeving vergeleken met het genexpressie patroon van leukemiën afkomstig 
van conventionele NSG muizenbeenmerg modellen. Hierbij werden opvallende verschillen ontdekt 
in de expressie van genen, geassocieerd met hypoxia, mitochondriën en metabolisme. Ook cellen van 
CML patiënten konden efficiënt getransplanteerd worden in de human scaffolds, waarbij de 
karakteristieken van de patiëntencellen beter behouden bleven dan in de conventionele 
muizenbeenmerg modellen. Samenvattend hebben we humaan beenmerg modellen ontwikkeld die 
de karakteristieken van myeloïde en lymphoïde cellen van BCR-ABL leukemiën goed nabootsen. 
Met behulp van deze modellen kunnen deze leukemiën nu in detail bestudeerd kunnen worden, zoals 
beschreven in hoofdstuk 3 van dit proefschrift [18]. 
 
Verhoogde afhankelijkheid van glutamine in cellen met het BCR-ABL gen 
 
In het begin van de 20ste eeuw veronderstelde Otto Warburg dat tumoren behandeld konden worden 
door de kankercellen “uit te hongeren” door ze te onthouden van energie [19]. Kankercellen zijn sterk 
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afhankelijk van glucose. Het Warburg effect, dat wil zeggen de verhoogde glucose opname en 
verbruik onder aerobe omstandigheden, is waarschijnlijk de meest opvallende metabole eigenschap 
van kanker cellen, en dit geldt ook voor CML cellen onder invloed van het BCR-ABL gen [20]. 
Hoewel er niet veel bekend is over de onderliggende mechanismen en consequenties van het Warburg 
effect, is het bekend dat wanneer het gebruik van glucose geblokkeerd wordt, kankercellen 
overschakelen op  andere voedingsstoffen zoals glutamine [21]. In dit proefschrift worden een aantal 
van deze eigenschappen in detail bestudeerd in de context van verschillende leukemieën. 
Verschillende oncogenen werden in humane HSCs tot expressie gebracht en het effect op het 
transcriptoom (dat wil zeggen de mate waarin genen “aan” staan) werd in detail bestudeerd. Onze 
resultaten lieten zien dat in het bijzonder de expressie van het BCR-ABL oncogen kon leiden tot het 
Warburg effect. Dit werd vergezeld door een verhoogde aanwezigheid van de glucose importerende 
eiwitten SLC2A1 en -3. Het metabole profiel van HSCs waarin BCR-ABL tot expressie werd 
gebracht ten opzichte van controles werd bepaald met behulp van NMR spectroscopie, een techniek 
waarbij de eigenschappen en de precieze hoeveelheid van moleculen in detail bestudeerd kan worden. 
Cellen werden gekweekt onder normoxia (normale zuurstof concentratie) en ook onder hypoxia 
(verlaagde zuurstof concentratie). Lactaat en pyruvaat gehaltes waren verhoogd in cellen met BCR-
ABL, zelfs onder normale zuurstof beschikbaarheid, hetgeen gepaard ging met een verhoogd 
glutamine metabolisme. De aanwezigheid van het glutamine importerende eiwit SLC1A5 was 
verhoogd in cellen met BCR-ABL, wat samen ging met een verhoogde gevoeligheid voor de 
glutaminase remmer BPTES. De opname van zuurstof nam ook af na BPTES behandeling, wat wijst 
op een glutamine afhankelijkheid voor de oxidatieve phosphorylering (de citroenzuurcyclus). De 
studie beschreven in hoofdstuk 4 suggereert dat BCR-ABL positieve kankercellen gebruik maken 
van een verhoogd glutamine metabolisme om de citroenzuurcyclus op gang te houden in cellen die 
afhankelijk zijn van glucose metabolisme [22]. 
 
Zoals beschreven in dit proefschrift is het gehumaniseerde beenmerg scaffold model bij uitstek 
geschikt om de afhankelijkheid van leukemische stamcellen van hun omgeving te bestuderen. 
Uiteindelijk zullen dit soort studies hopelijk een bijdrage kunnen leveren aan de ontwikkeling van 
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